On this page
Quick Reference
Overview and Recommendations
Background
- •Endometriosis is an estrogen-dependent chronic inflammatory disorder defined by the presence of endometrium-like tissue (glands and stroma) outside the uterine cavity, affecting approximately 10% of reproductive-age individuals worldwide, an estimated 9 million women in the United States. Untreated, it carries a substantial burden of chronic pelvic pain and subfertility, with diagnostic delay averaging 6.7 years from symptom onset and patients often consulting three or more clinicians before obtaining a definitive diagnosis.
- •The disease presents in three major phenotypes that may coexist and are increasingly considered distinct diseases with different pathogenic mechanisms: superficial peritoneal endometriosis (most common, often in adolescents with clear or red lesions), ovarian endometriomas (bilateral in 30-50%, associated with a 54.3% reduction in AMH), and deep infiltrating endometriosis (DIE, infiltration >5 mm into subperitoneal tissue, involving rectovaginal septum, bowel, bladder, or ureters).
- •Pathogenesis is driven by a tripartite mechanism: retrograde menstruation (supported by an 8.63-fold increased risk of retrograde uterine contraction pattern during menses), progesterone resistance (mediated by YAP1 upregulation of miR-21-5p suppressing progesterone receptor expression), and chronic inflammation with immune evasion, dysbiosis, and central sensitization that amplifies pain.
- •Endometriosis is heritable with polygenic/epigenetic susceptibility; lesions can be clonal with acquired genetic instability. It is associated with a 1.3-fold increased risk of pregnancy loss, a 2-fold increased risk of , a 1.3-fold increased risk of , and a 1.5-fold increased risk of ovarian cancer (especially endometrioid and clear cell subtypes), with the highest risk among women with DIE and ovarian endometriomas (aHR 9.66).
- •Classification uses three systems serving distinct purposes: revised ASRM staging (I-IV) for research and infertility prognosis (though it correlates poorly with pain severity), the #Enzian classification for compartment-based surgical mapping of deep disease (A: rectovaginal, B: uterosacral/cardinal, C: rectum), and the Endometriosis Fertility Index (EFI, 0-10) for predicting spontaneous pregnancy rates after surgery. No single system predicts all outcomes.
Evaluation
- •Suspect endometriosis in any reproductive-age woman presenting with dysmenorrhea (often beginning before menses and persisting through flow), deep dyspareunia, nonmenstrual pelvic pain, or infertility, 90% of affected individuals report pelvic pain, and 26% experience infertility.
- •Ask about pain timing and character: cyclic vs constant, relation to menstruation, dyschezia (painful defecation), diarrhea or constipation, dysuria, hematuria, or rectal bleeding. Inquire about family history (2.75-fold increased risk with affected sibling), previous pelvic surgeries, childhood adversity (HR 1.20-1.61), and fertility desires and duration of infertility.
- •Perform a bimanual pelvic examination, ideally during menstruation when lesions are more tender and palpable, examine for tender nodules in the posterior fornix, fixed retroverted uterus, uterosacral ligament nodularity, and adnexal masses. Sensitivity is only 25-50%, so a normal examination does not exclude disease, especially superficial peritoneal endometriosis.
- •Order transvaginal ultrasound (TVS) as first-line imaging, preferably with an endometriosis-trained sonographer. For DIE, TVS has pooled sensitivity 79-91% and specificity 94-98%; for ovarian endometriomas, detection rates exceed 90%. A negative TVS does not rule out superficial peritoneal disease but can diagnose advanced disease without laparoscopy.
- •Obtain pelvic MRI when TVS is inconclusive or for surgical mapping of deep endometriosis; MRI has pooled sensitivity 91-94% and specificity 86-88% for DIE, and is less operator-dependent. MRI is not recommended as a primary screening tool due to cost.
- •Check serum CA-125 (threshold ≥30 U/mL) as a rule-in test: pooled specificity is 93% (95% CI 89-95%) but sensitivity is only 52% (38-66%), with higher sensitivity for moderate-to-severe disease (63%) than minimal (24%). A positive result supports the diagnosis, but a negative result cannot rule out endometriosis.
- •Consider diagnostic laparoscopy with histologic confirmation as the gold standard when imaging is negative but clinical suspicion remains high, or when surgical treatment is planned for pain or infertility. Direct visualization of endometriotic lesions followed by biopsy provides the highest diagnostic accuracy.
- •Apply the structured diagnostic algorithm: Step 1, clinical suspicion based on symptoms; Step 2, pelvic examination and first-line TVS; Step 3, if TVS shows ovarian endometrioma or DIE, diagnosis is established without laparoscopy; Step 4, if TVS is negative or equivocal but suspicion high, obtain pelvic MRI; Step 5, if MRI is negative or suggests only superficial disease, offer diagnostic laparoscopy.
- •Evaluate for coexisting conditions including (up to 85% of endometriosis patients, exacerbating uterine contractility and pain), irritable bowel syndrome (OR 3.5), and pelvic inflammatory disease (OR 5.9), these share symptoms and may be misdiagnosed or co-occur.
- •Assess fertility status: document age, duration of infertility, ovarian reserve (AMH, antral follicle count), and prior pregnancy history. Postoperatively, calculate the Endometriosis Fertility Index (EFI) to predict spontaneous conception, cumulative pregnancy rate at 36 months ranges from 10% (EFI 0-2) to 69% (EFI 9-10).
Management
- •Initiate first-line medical therapy for pain in premenopausal women not seeking immediate pregnancy: a combined hormonal contraceptive (CHC, continuous or cyclic) or a progestin-only agent such as 2 mg orally once daily. In network meta-analysis, dienogest reduced pelvic pain (SMD -1.20, 95% CI -1.78 to -0.61) and CHC reduced pain (SMD -0.67, 95% CI -1.25 to -0.09) versus placebo.
- •If first-line therapy fails after 3-6 months of adherence, escalate to an oral GnRH antagonist with add-back therapy: 200 mg twice daily with estradiol 1 mg/norethindrone acetate 0.5 mg add-back, combination therapy (40 mg/1 mg/0.5 mg) once daily, or 200 mg daily with add-back. Dysmenorrhea responder rates at 3 months are 72-76% versus 20-24% with placebo.
- •Do not use GnRH agonists (leuprolide, nafarelin) for more than 6 months without add-back therapy, lumbar spine bone mineral density loss exceeds 2% at 6 months. Add-back with estradiol 1 mg/norethindrone acetate 0.5 mg daily stabilizes BMD and can extend therapy safely.
- •Refer for laparoscopic surgery when medical therapy fails, pain is refractory, large endometriomas (>3 cm) are present, or fertility is desired with resectable disease. Excision of lesions is preferred over ablation for deep disease and endometriomas, it allows histologic confirmation and more complete removal, and improves overall pain at 6 months (OR 6.58) and live birth rates (OR 1.94) versus diagnostic laparoscopy alone.
- •For ovarian endometriomas, perform rather than drainage or ablation, cystectomy reduces recurrence (OR 0.12 with postoperative LNG-IUS). Preserve ovarian cortex to protect fertility; bilateral endometriomas reduce AMH by 54.3%. Avoid coagulation of the ovarian hilum to minimize damage to ovarian reserve.
- •Stage surgically using rASRM and EFI, the EFI guides fertility counseling: if EFI ≥5, attempt natural conception for 6-12 months; if EFI <5 or age >38, proceed directly to ART without additional surgical delay. Ovulation suppression agents (GnRH agonists, progestins) do not improve pregnancy rates and should not be used for infertility alone.
- •After surgery, initiate long-term hormonal suppression to prevent recurrence: CHC, progestin (dienogest 2 mg daily), or the (LNG-IUS). LNG-IUS is the most effective postoperative agent, reducing endometrioma recurrence (OR 0.12, 95% CI 0.02-0.63) and pain scores (MD -24.96 on VAS). Continue suppression until pregnancy is desired or menopause.
- •In pregnancy, manage pain with paracetamol; avoid NSAIDs after 20 weeks (risk of and premature ductus arteriosus closure). GnRH agonists and hormonal contraceptives are contraindicated once pregnancy is confirmed. Classify pregnancies in women with stage III-IV endometriosis or DIE as high-risk and offer serial ultrasound for fetal growth, placental position, and cervical length.
- •Acute management of spontaneous hemoperitoneum in pregnancy (SHiP), suspected by acute abdominal pain with hypovolemic shock, requires emergency laparotomy with oversewing of bleeding implants and possible concurrent cesarean delivery if the fetus is viable ≥24 weeks. SHiP incidence is 4.9 per 100,000 births with median blood loss 2000 mL; maternal mortality is low with prompt surgery.
- •For postmenopausal women with residual disease or de novo pain, use progestogen monotherapy (oral micronized progesterone 200 mg/day or norethindrone acetate 5 mg/day) as preferred hormone therapy to avoid estrogen-driven reactivation. Aromatase inhibitors such as 2.5 mg daily may be used for refractory pain. External beam radiation (1500-2100 cGy) to ovarian remnants is a last-resort option.
- •Monitor for recurrence: endometrioma recurrence after cystectomy reaches 27% at 24 months without suppression; pain recurrence after bowel resection for DIE is 24%, with reintervention in 19%. Counsel patients that the disease is chronic with high recurrence risk without ongoing hormonal suppression.
- •Avoid: performing hysterectomy or as first-line treatment for pain (25% have recurrent pain post-hysterectomy); using danazol (androgenic side effects); performing laparoscopic uterine nerve ablation (LUNA), two large RCTs showed no benefit for endometriosis-associated pain; using GnRH antagonist monotherapy without add-back for >6 months (bone loss); and using ovulation suppression for infertility alone (no pregnancy benefit).
- •Refer to a multidisciplinary team for deep infiltrating endometriosis requiring bowel, bladder, or ureteral surgery, shaving has fewer major complications than segmental resection (6.7% vs 24%). Refer to a fertility specialist if EFI <5 or age >38 with infertility. For adolescents, refer for laparoscopy if pain persists despite 3-6 months of empiric CHC or NSAID therapy.
Board Review — High Yield
- •Sampson's hypothesis, retrograde menstruation is the primary pathogenic mechanism; supported by an 8.63-fold increased risk of retrograde uterine contraction pattern during menses in endometriosis.
- •Triple classification system, rASRM (research), #Enzian (surgical mapping), EFI (fertility prognosis); no single system predicts all outcomes.
- •Three phenotypes, superficial peritoneal, ovarian endometrioma (bilateral in 30-50%, reduces AMH by 54.3%), and deep infiltrating endometriosis (DIE, >5 mm infiltration), may represent distinct diseases.
- •Progesterone resistance, mediated by YAP1 upregulation of miR-21-5p suppressing progesterone receptor; explains limited efficacy of progestin monotherapy.
- •CA-125, rule-in test with 93% specificity but only 52% sensitivity; more useful in moderate-severe disease (63% sensitivity). Negative test does not rule out.
- •GnRH antagonists with add-back, elagolix, relugolix CT, and linzagolix achieve 72-76% dysmenorrhea response at 3 months with <1% BMD decline over 2 years when used with add-back.
- •Endometriosis Fertility Index (EFI), validated postoperative score guiding need for ART; EFI ≥5 → attempt natural conception 6-12 months; EFI <5 or age >38 → proceed to IVF.
- •Spontaneous hemoperitoneum in pregnancy (SHiP), rare (4.9/100,000 births) but life-threatening; requires emergency laparotomy with oversewing of bleeding implants and possible cesarean delivery.
- •Ovarian cancer risk, 4.2-fold increased risk, especially type I (endometrioid/clear cell, aHR 7.48); absolute lifetime risk <2-5%; routine screening not recommended.
- •Diagnostic delay, averages 6.7 years from symptom onset, with patients consulting a mean of three clinicians before diagnosis; transvaginal ultrasound can diagnose advanced disease without laparoscopy.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Endometriosis is defined by the presence of endometrium-like tissue outside the uterus, with three main phenotypes: superficial peritoneal, ovarian endometrioma, and deep infiltrating endometriosis.
- ▸Three complementary classification systems are used: rASRM (staging), #Enzian (compartment mapping for deep disease), and Endometriosis Fertility Index (prognosis for spontaneous conception).
- ▸Affects ~10% of reproductive-age women; associated with significant morbidity including chronic pelvic pain, infertility, adverse pregnancy outcomes, and increased ovarian cancer risk.
Endometriosis is an estrogen-dependent chronic inflammatory disorder defined by the presence of endometrium-like tissue (glands and stroma) outside the uterine cavity, most commonly on the pelvic peritoneum, ovaries, and rectovaginal septum [15]D5.
Also Called / Synonyms: endometriosis interna (adenomyosis, now considered a distinct entity), endometriosis externa, endometrioma (ovarian endometriosis), deep infiltrating endometriosis (DIE), adenomyosis externa (for deep disease), and historically "chocolate cysts" for ovarian endometriomas. Abbreviations: rASRM (revised American Society for Reproductive Medicine), EFI (Endometriosis Fertility Index), DIE, SUP (superficial peritoneal endometriosis), OMA (ovarian endometrioma).
Phenotypes: Endometriosis presents in three main phenotypes, which may coexist and are considered by some experts to be distinct diseases with different pathogenic mechanisms [39]D5[42]D5.
| Phenotype | Key Distinguishing Feature | Associated Notes |
|---|---|---|
| Superficial peritoneal endometriosis (SUP) | Implants on peritoneal surfaces, often red, black, or clear vesicles | Most common in adolescents; may be early stage [42]D5 |
| Ovarian endometrioma (OMA) | Cystic lesion within the ovary lined by endometrium-like tissue | Bilateral in 30-50%; associated with reduced AMH levels (‑54.3% versus no endometriosis) [22]B2b |
| Deep endometriosis (DE) | Infiltration >5 mm into the subperitoneal tissue, often involving the rectovaginal septum, uterosacral ligaments, bowel, or bladder | Defined as "adenomyosis externa" [43]D5; single nodule >1 cm in most cases; prevalence 1‑2% [43]D5 |
Classification Systems: Three systems are used in clinical practice, each serving a distinct purpose [46]A1c.
- rASRM staging (I-IV): Based on lesion appearance, extent, and adhesions; correlates poorly with pain but moderately with infertility [16]C4[53]B2a.
- #Enzian classification: A compartment-based system (A: rectovaginal, B: uterosacral/cardinal, C: rectum, plus O: ovary, T: tubo‑ovarian) that predicts surgical complexity and is used for deep disease [28]B2b[36]B2b.
- Endometriosis Fertility Index (EFI): Postoperative score (0-10) that predicts spontaneous pregnancy rates after surgery; validated and highly reproducible [29]B2b[40]B2b.
Clinical Significance: Endometriosis affects approximately 10% of reproductive‑age individuals globally [15]D5 and is a leading cause of chronic pelvic pain and subfertility. It is associated with a 1.3‑fold increased risk of pregnancy loss [12]B2b, a 2‑fold higher risk of [13]B2b, and a 1.3‑fold increase in [13]B2b. The condition also carries a 1.5‑fold increased risk of ovarian cancer (endometriosis‑associated ovarian cancer, EAOC) [31]D5[51]B3b. Diagnostic delay averages 0.3 to 12 years, underscoring the need for improved recognition [1]B2a.
Pearl: Use the three-system classification toolbox (rASRM for staging, #Enzian for deep disease mapping, EFI for fertility prognosis) to guide surgical planning and patient counselling [46]A1c. The next section, Pathophysiology & Mechanism, explores the genetic, epigenetic, and inflammatory pathways that drive disease initiation and progression.
Pathophysiology & Mechanism
- ▸Retrograde menstruation is nearly universal, but endometriosis develops only in those with impaired immune clearance and/or genetic/epigenetic susceptibility.
- ▸Progesterone resistance, mediated by YAP1/miR-21-5P pathway, impairs decidualization and contributes to lesion persistence and infertility.
- ▸Aberrant uterine contractility (8.63-fold increased risk of retrograde pattern) and altered placentation link endometriosis to adverse obstetric outcomes.
The classification of endometriosis into peritoneal, ovarian, and deep infiltrating phenotypes reflects distinct pathogenic mechanisms that converge on a common core: the survival and proliferation of endometrial tissue outside the uterus. A tripartite model, retrograde menstruation with impaired clearance, progesterone resistance, and chronic inflammation, explains the spectrum of clinical sequelae.
Retrograde Menstruation and Uterine Dysfunction
Sampson's hypothesis of retrograde menstruation has been substantiated by meta-analytic evidence demonstrating an 8.63-fold increased risk of retrograde uterine contraction pattern during menses in women with endometriosis versus controls [60]B2a. Contraction frequency is higher in both menstrual and luteal phases (mean difference 0.82 and 0.52 contractions/min, respectively), and amplitude is increased across all cycle phases [60]B2a. This mechanical dysfunction impairs uterotubal transport, contributing to infertility even with patent tubes [82]B2b. Neonatal uterine bleeding, occurring in 5-10% of newborns, may implant endometrial stem/progenitor cells in the pelvis, providing a substrate for premenarcheal and adolescent endometriosis [42]D5[74]D5.
Genetic and Epigenetic Susceptibility
Endometriosis is a heritable, polygenic/polyepigenetic disease [39]D5[42]D5. Lesions are clonal, and the set of inherited epigenetic marks determines predisposition, while additional somatic events drive progression. Peritoneal, ovarian endometrioma, and deep infiltrating lesions may represent three distinct diseases with different evolutionary trajectories [39]D5. The clonal origin of endometriomas and deep nodules is consistent with a model of acquired genetic instability [42]D5.
Hormonal Dysregulation: Estrogen Dependence and Progesterone Resistance
Endometriotic lesions are estrogen-dependent, express aromatase, and are resistant to progesterone's anti-proliferative effects. A key mechanism is activation of the Hippo/YAP1 pathway: YAP1 upregulates miR-21-5p, which suppresses progesterone receptor (PGR) expression, impairing decidualization [108]D5. The YAP1 inhibitor verteporfin restores PGR and enhances progestin efficacy in a mouse model [108]D5. This progesterone resistance explains the limited efficacy of progestin monotherapy and the rationale for ovariostasis, reversible suppression of cyclic ovarian activity, as a preventive and therapeutic strategy [112]D5.
Inflammation, Immune Evasion, and Pain
Chronic inflammation is sustained by activated macrophages, pro-inflammatory cytokines, and prostaglandins. Impaired natural killer cell activity allows lesion persistence. Gut and reproductive tract dysbiosis, enrichment of Proteobacteria and depletion of Lactobacillus, may contribute via enhanced β-glucuronidase activity and estrogen recirculation [117]B3a. Pain is not merely nociceptive; central sensitization, pelvic floor dysfunction, and psychosocial factors amplify the pain experience [80]D5. The concurrent presence of adenomyosis, found in up to 85% of women with endometriosis, further exacerbates uterine contractility and pain [82]B2b[116]D5.
Impact on Fertility and Placentation
Progesterone resistance and inflammation impair endometrial receptivity [104]D5. Ovarian endometriomas reduce ovarian reserve and oocyte quality through oxidative stress and fibrosis [70]D5. Aberrant trophoblast invasion due to an altered endometrial environment predisposes to (adjusted OR 5.90 in primiparous women [113]B2b) and spontaneous hemoperitoneum in pregnancy (SHiP) [67]C4. Comorbid adenomyosis synergistically increases the risk of preterm birth, preeclampsia, and small-for-gestational-age infants [89]B2b[116]D5.
Pearl: The mechanistic triad of retrograde menstruation, progesterone resistance, and chronic inflammation underpins both pain and infertility in endometriosis; targeting each component, hormonally, surgically, and through pain science, is essential for effective .
Epidemiology, Etiology & Risk Factors
- ▸Endometriosis affects 6-10% of reproductive-age women, with diagnosis peaking in the early 30s.
- ▸Black women are less likely to be diagnosed; Asian women more likely compared with White women.
- ▸Family history (especially twin), early menarche, low BMI, nulliparity, cesarean delivery, and childhood adversity are key risk factors; adolescent dairy and citrus intake may be protective.
Building on the understanding of retrograde menstruation and immune dysregulation, the epidemiologic architecture of endometriosis reveals a complex interplay of genetic, reproductive, and environmental factors that shape disease burden and risk. Endometriosis affects up to 10% of reproductive-age women worldwide, an estimated 9 million women in the United States [85]D5[162]D5. A population-based Australian cohort reported a cumulative prevalence of clinically confirmed endometriosis of **6.0% ** by age 40-44 years, rising to 11.4% when clinically suspected cases are included [133]B2b. Age-specific incidence peaks at 6 per 1000 person-years at age 30-34 years [133]B2b. In the UK, prevalence increased from 119.7 per 10,000 population in 1998 to 201.3 per 10,000 in 2017, while incidence remained stable at approximately 12 per 10,000 person-years [135]B3b.
Demographic Distribution
Race and ethnicity influence diagnosis. Compared with White women, Black women are less likely to be diagnosed (OR 0.49, 95% CI 0.29-0.83), whereas Asian women are more likely (OR 1.63) [126]A1a. Hispanic women showed no statistically significant difference (OR 0.46, 95% CI 0.14-1.50) [126]A1a. These disparities may reflect differences in access to care, diagnostic bias, or true biologic variation. No significant differences in prevalence were found between lesbian/bisexual and heterosexual women [125]B2a.
Temporal Trends
The prevalence of diagnosed endometriosis has risen over recent decades, likely driven by increased surgical detection and awareness rather than a true increase in incidence [135]B3b. Incidence rates have remained stable in population-based studies [135]B3b.
Risk Factors
Table 1. Key Risk Factors for Endometriosis
| Factor | Effect Estimate (OR/RR/HR) | 95% CI | Evidence Level |
|---|---|---|---|
| Non-modifiable | |||
| Family history (affected sibling) | IRR 2.75 | 2.25-3.36 | Cohort [136]B3b |
| Affected twin | IRR 6.98 | 4.19-11.62 | Cohort [136]B3b |
| Obstructive Müllerian anomaly | Increased prevalence (qualitative) | - | Meta-analysis [10]B2a |
| Younger age at menarche | HR ~1.2 (per year earlier) | - | Cohort [85]D5 |
| Shorter menstrual cycle length | OR ~1.3 | - | Cohort [85]D5 |
| Modifiable / associated | |||
| Low body mass index | OR ~1.4 | - | Cohort [85]D5 |
| Nulliparity | OR ~1.5 | - | Cohort [85]D5 |
| Cesarean section | HR 1.8 | 1.7-1.9 | Cohort [4]B2b |
| Severe teenage acne | HR 1.20 | 1.08-1.32 | Cohort [180]B2b |
| Childhood adversity (any) | HR 1.20 | 1.17-1.24 | Cohort [148]B3b |
| Childhood adversity (5+ events) | HR 1.61 | 1.37-1.88 | Cohort [148]B3b |
| Higher adolescent dairy intake | HR 0.68 | 0.47-0.96 | Cohort [161]B2b |
| Higher citrus fruit intake | RR 0.78 | 0.69-0.89 | Cohort [178]B2b |
| Smoking (with family history) | IRR 4.28 | 2.43-7.55 | Cohort [136]B3b |
| Early menarche (with family history) | IRR 3.47 | 2.82-4.26 | Cohort [136]B3b |
Protective Factors
Higher parity is associated with lower odds of endometriosis (OR 0.44, 95% CI 0.24-0.81) [142]B2b. Adolescent dairy consumption of >4 servings/day reduced risk by 32% compared with ≤1 serving/day [161]B2b. Citrus fruit intake of ≥1 serving/day reduced risk by 22% [178]B2b.
Special Considerations
Gene-environment interactions are substantial: women with both a family history and smoking have a 4.3-fold increased risk beyond additive effects [136]B3b. Childhood adversity, including exposure to violence (HR 2.38), is a newly recognized risk factor [148]B3b. Seasonal variation in diagnosis has not been consistently reported.
Pearl: When counseling a patient with first-degree relative affected, consider additive risk from early menarche, low BMI, and smoking, these modifiable factors can amplify genetic risk 3- to 4-fold [136]B3b.
Clinical Presentation
- ▸Pelvic pain (dysmenorrhea, nonmenstrual pain, dyspareunia) is the dominant symptom, reported by 90% of patients, and infertility by 26%.
- ▸Diagnostic delay averages 6.7 years, with work productivity loss of 10.8 hours per week; depressive symptoms are common and mediated by chronic pain.
- ▸Phenotypic variants, superficial peritoneal, endometrioma, deep infiltrating, and extragenital, each have distinct clinical presentations and require tailored diagnostic suspicion.
From these epidemiologic patterns, the clinical portrait of endometriosis emerges as a syndrome dominated by pain and infertility but extending far beyond the pelvis. The presentation is heterogeneous, often discordant with disease stage, and shaped by lesion location, depth, and host inflammatory response [85]D5[162]D5.
Presenting Symptoms
Pain is the hallmark: 90% of affected individuals report pelvic pain, including dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia [85]D5. Dysmenorrhea typically begins before menses and persists through the flow; nonmenstrual pain may be constant or cyclic. Deep dyspareunia, often described as a sharp, thrust‑sensitive pain, is a common and distressing symptom, reported in 40-60% of patients [191]A1a[192]A1b. Bowel and bladder symptoms include dyschezia, diarrhea, constipation, and, with deep infiltrating disease, rectal bleeding or tenesmus [199]C4[210]D5. Urinary symptoms, dysuria, urgency, or hematuria, signal bladder involvement. Infertility occurs in 26% of women with endometriosis [85]D5. The impact extends beyond physical symptoms: affected women lose a mean 10.8 hours of work weekly owing to reduced effectiveness, and diagnostic delay averages 6.7 years from symptom onset to surgical diagnosis [224]B2c. Depressive symptoms are significantly more common among those with endometriosis (standardized mean difference 0.22 vs. controls), driven largely by chronic pelvic pain [190]B2a.
Examination Findings
Pelvic examination may reveal tender, nodular uterosacral ligaments, a fixed retroverted uterus, or a palpable adnexal mass (endometrioma). However, a normal examination does not exclude disease, particularly superficial or early‐stage endometriosis [217]D5. With deep infiltrating disease involving the sacral plexus, neurological findings, ipsilateral lower‑extremity dysesthesia, paresthesia, chronic radiating pain, or motor weakness, may be elicited [219]C4. In a series of 27 women with sacral plexus endometriosis, the most common neurological symptoms were dysesthesia (n = 17) and paresthesia (n = 10) [219]C4.
Phenotypic Variants
| Variant | Key Features | Approximate Frequency |
|---|---|---|
| Superficial peritoneal endometriosis | “Powder‑burn” lesions on peritoneum; may cause pain disproportionate to lesion size | Most common; ~80% of cases [220]B3b |
| Ovarian endometrioma | Cystic ovarian mass with “ground‑glass” echogenicity on ultrasound; risk of rupture and torsion | ~20-40% of those with endometriosis [221]B3b |
| Deep infiltrating endometriosis (DIE) | Infiltrates >5 mm into peritoneum; involves uterosacral ligaments, rectovaginal septum, bowel, bladder, or ureters | ~15-20% [143]B2b[202]B2b |
| Extragenital endometriosis | Thoracic (catamenial pneumothorax, hemoptysis), inguinal (cyclical groin mass), sciatic (cyclical ), or appendiceal (catamenial appendicitis) | Rare; ~1-5% [203]C4[205]C4[215]C4[237]C4 |
Red Flags
Acute‑onset severe pelvic or abdominal pain, especially with signs of peritonitis or hypovolemia, should raise suspicion for spontaneous hemoperitoneum in pregnancy (SHiP), a rare but life‑threatening complication associated with endometriosis [67]C4. In the largest series, SHiP occurred predominantly in the second and third trimesters, with median blood loss 2000 mL [67]C4. Catamenial pneumothorax (recurrent pneumothorax within 72 hours of menses) requires urgent thoracic surgical consultation. Acute urinary retention from bladder DIE or ureteral obstruction likewise demands immediate intervention.
Atypical Presentations
Inguinal endometriosis mimics a hernia or lymphadenopathy, presenting as a cyclical groin lump that resolves after menses [205]C4[215]C4. Sciatic endometriosis causes cyclical radicular pain, often misdiagnosed as lumbar radiculopathy [175]A1a[219]C4. Catamenial appendicitis, recurrent right lower quadrant pain with menses, without appendiceal inflammation on pathology, may be due to mast cell activation in the appendiceal wall [203]C4. Postmenopausal women may present with a pelvic mass, bleeding, or obstructive symptoms, mimicking malignancy [206]C4.
These varied presentations underscore the need for a systematic diagnostic approach, detailed in the next section.
Pearl: The absence of a palpable pelvic mass or normal imaging does not rule out endometriosis, superficial peritoneal disease, which accounts for most cases, often eludes examination and ultrasound, yet causes debilitating pain.
Diagnosis & Workup
- ▸Laparoscopy with histology is the gold standard, but non-invasive imaging (TVS and MRI) is diagnostic for ovarian endometriomas and deep endometriosis, reducing the need for surgery.
- ▸Transvaginal ultrasound is the first-line imaging modality, with high specificity (94-98%) for deep endometriosis; a negative scan does not exclude disease.
- ▸Serum CA-125 ≥30 U/mL is a rule-in test (specificity 93%) but lacks sensitivity (52%); no other biomarker is clinically validated for routine use.
The clinical presentation of chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility should prompt a systematic diagnostic workup. Despite advances in imaging, the diagnosis of endometriosis remains delayed by an average of 5 to 12 years, with most women consulting three or more clinicians before obtaining a definitive diagnosis [85]D5[224]B2c. A structured approach, combining clinical suspicion, pelvic examination, imaging, and when indicated, laparoscopy, reduces this delay and enables timely intervention.
Gold-Standard Test
Laparoscopy with histologic confirmation remains the gold standard for the definitive diagnosis of endometriosis [69]D5[187]A1c[195]A1c. Direct visualization of endometriotic lesions, followed by biopsy for histopathologic confirmation, provides the highest diagnostic accuracy. However, laparoscopy is invasive, carries surgical risk, and is not required when non-invasive imaging is diagnostic for advanced disease, particularly ovarian endometriomas or deep endometriosis [217]D5[266]B2a.
Imaging
Transvaginal ultrasound (TVS) is the first-line imaging modality [32]D5[33]D5[187]A1c. For deep infiltrating endometriosis (DIE), TVS has a pooled sensitivity of 79% to 91% and specificity of 94% to 98% [137]A1a[245]B2a[246]B2a. For rectosigmoid DIE, sensitivity and specificity are 85% and 96%, respectively [137]A1a. For ovarian endometriomas, detection rates exceed 90% [252]A1c. TVS also accurately detects parametrial involvement (specificity 98%, sensitivity 63% to 85%) [138]A1a[140]A1a. A negative TVS does not exclude endometriosis, especially superficial peritoneal disease [247]D5.
Pelvic magnetic resonance imaging (MRI) is reserved for inconclusive TVS, suspected deep endometriosis requiring surgical mapping, or when TVS is contraindicated or poorly tolerated [187]A1c[248]B2a. MRI for DIE has a pooled sensitivity of 91% to 93.5% and specificity of 86% to 87.5% [248]B2a. For rectosigmoid DIE, sensitivity and specificity reach 92% and 96%, respectively [266]B2a. MRI is less operator-dependent than TVS but more costly; it should not be used as a primary screening tool [248]B2a.
Artificial intelligence (AI) applied to ultrasound and MRI is an emerging field, with classification models distinguishing normal from pathological cases with promising accuracy, but external validation is lacking [5]B2a[247]D5.
Laboratory Studies
Serum CA-125 (≥30 U/mL) is the only blood test in routine clinical use for endometriosis [194]B2a. Pooled specificity is 93% (95% CI, 89-95%) and sensitivity 52% (95% CI, 38-66%) [194]B2a. CA-125 is more sensitive for moderate-to-severe disease (63%) than for minimal disease (24%) [194]B2a. It performs as a rule-in test: a positive result supports the diagnosis, but a negative result cannot rule out endometriosis [194]B2a[258]B2a.
Investigational biomarkers include serum microRNA panels (area under the curve 0.94 in one study) [20]B3b, plasma protein panels (AUC 0.997 for severe endometriosis vs symptomatic controls) [235]B3b, and saliva microRNA signatures [253]B2c. None have been clinically validated for routine use [265]D5.
Pelvic Examination
Bimanual pelvic examination may reveal tender nodules in the posterior fornix, fixed retroversion of the uterus, or adnexal masses. However, sensitivity is low (25% to 50%) and negative examination does not exclude disease [187]A1c[266]B2a. Examination is most useful when performed during menstruation, when lesions are more tender and palpable [209]D5.
Diagnostic Algorithm
Step 1: Clinical suspicion based on symptoms (dysmenorrhea, nonmenstrual pelvic pain, dyspareunia, infertility) [85]D5[187]A1c.
Step 2: Pelvic examination and first-line TVS (preferably with an endometriosis-trained sonographer) [32]D5[187]A1c.
Step 3: If TVS shows ovarian endometrioma or DIE → diagnosis is established; proceed to without laparoscopy [33]D5[217]D5.
Step 4: If TVS is negative or equivocal but clinical suspicion remains high → obtain pelvic MRI [187]A1c[248]B2a.
Step 5: If MRI is negative or only superficial disease is suspected → offer diagnostic laparoscopy for definitive diagnosis and treatment [69]D5[187]A1c.
Pearl: A negative transvaginal ultrasound does not rule out endometriosis; laparoscopy remains indicated in symptomatic patients with high clinical suspicion.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Can endometriosis be diagnosed without surgery? | ACOG 2026: Clinical diagnosis is acceptable when imaging is diagnostic for endometrioma or DIE [187]A1c | ESHRE 2014: Laparoscopy remains the gold standard for all subtypes [195]A1c | Moderate | Imaging is sufficient for advanced disease; laparoscopy is needed for superficial disease |
| Role of CA-125 | ACOG: Optional, not diagnostic [187]A1c | Cochrane: Rule-in test with high specificity [194]B2a | Weak | May support diagnosis but should not be used alone |
| Modality | Target | Pooled Sensitivity | Pooled Specificity | Reference |
|---|---|---|---|---|
| TVS | Deep infiltrating endometriosis | 79-91% | 94-98% | [137]A1a[245]B2a[246]B2a |
| TVS | Rectosigmoid DIE | 85% | 96% | [137]A1a |
| TVS | Ovarian endometrioma | >90% | >95% | [252]A1c |
| MRI | Deep infiltrating endometriosis | 91-93.5% | 86-87.5% | [248]B2a |
| MRI | Rectosigmoid DIE | 92% | 96% | [266]B2a |
Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis
- ▸Endometriosis with diffuse adenomyosis is a strong independent risk factor for SGA (OR 3.744) and requires serial growth scans and uterine artery Doppler.
- ▸Decidualized endometriomas can mimic ovarian malignancy on ultrasound; follow‑up after delivery confirms benign nature.
- ▸Invasive prenatal diagnosis may be technically challenging in women with endometriosis due to pelvic adhesions; uterine manipulation with transvaginal probe can aid CVS.
Following the diagnosis of endometriosis, either preconception or during early pregnancy, antenatal surveillance for the fetus is structured around four pillars that address the specific risks conferred by the disease.
Aneuploidy and Anomaly Screening
First-trimester combined screening (nuchal translucency, PAPP‑A, free β‑hCG) is offered at 11-13⁺⁶ weeks. Women with endometriosis and coexisting diffuse adenomyosis have significantly lower PAPP‑A (0.61 vs 0.88 multiple of the median, P<0.001) [89]B2b, which may reflect placental dysfunction rather than aneuploidy. The mid‑trimester anatomy scan at 18-22 weeks should include careful evaluation of the adnexa, as decidualized endometriomas can mimic ovarian malignancy, appearing as irregular thick inner walls, hyperechoic papillary projections, and high vascularity [282]B2b. These changes typically regress after delivery, reassuring the benign nature [282]B2b. No increased risk of structural anomalies is attributed to endometriosis per se.
Growth and Doppler Surveillance
Women with endometriosis, particularly those with diffuse adenomyosis, are at high risk of delivering a small‑for‑gestational‑age (SGA) infant. The incidence of SGA reaches 40% in the presence of diffuse adenomyosis versus 10.8% in endometriosis only (OR 3.744, 95% CI 1.158‑12.099) [89]B2b. Uterine artery Doppler reveals higher pulsatility index in the first (2.23 vs 1.67) and second (1.30 vs 0.94) trimesters in women with diffuse adenomyosis, indicating impaired placentation [89]B2b. Consequently, serial growth scans every 4 weeks from 24 weeks’ gestation, combined with uterine artery Doppler at the 20‑24 week anatomy scan, are recommended for this subgroup. Women with deep infiltrating endometriosis (DIE) alone also face increased risks of preterm birth (31.7%), (17.8%), and , warranting a low threshold for enhanced surveillance [281]B2b.
Fetal Well‑Being Testing
Indications for fetal well‑being testing (non‑stress test, biophysical profile) arise when growth restriction, , or preeclampsia develop. The systematic review by Leone Roberti Maggiore et al. confirms an association between endometriosis and preterm birth, SGA, and placenta previa (OR 1.67 to 15.1) [284]D5. Antenatal corticosteroids for fetal lung maturity should be considered when preterm delivery is anticipated, following standard protocols.
Invasive Prenatal Diagnosis
Chorionic villus sampling (CVS) and are performed per standard indications. However, in women with endometriosis, pelvic adhesions or a fixed retroflexed uterus may render transabdominal CVS technically challenging. The transvaginal probe can be used as a uterine manipulator to reposition the trophoblast, facilitating access [287]C4. In one series, 90 of 1539 TA‑CVS procedures required uterine manipulation; in one case, CVS was abandoned due to significant pelvic pain in a patient with endometriosis and a fixed retroflexed uterus [287]C4. Pre‑procedure ultrasound assessment of uterine mobility and ovarian endometriomas is prudent. Amniocentesis is generally feasible, but clinicians should be aware of potential adhesions.
Pearl: In women with endometriosis and diffuse adenomyosis, serial growth scans from 24 weeks and uterine artery Doppler at 20‑24 weeks are essential to detect the 40% risk of SGA. The decidualized endometrioma may mimic ovarian malignancy, but follow‑up after delivery confirms its benign nature.
Severity, Staging & Risk Stratification
- ▸rASRM staging has moderate interrater reliability (κ=0.44) and does not predict pain severity but correlates with ovarian reserve (stage III-IV associated with 40% lower AMH).
- ▸The EFI is the validated tool for predicting pregnancy after surgical staging; the Enzian classification and UBESS guide surgical planning and complexity.
- ▸Endometriosis increases ovarian cancer risk modestly (RR 1.3-4.2), but absolute lifetime risk remains <2-5%; routine surveillance or prophylactic surgery is not indicated based on endometriosis alone.
Following the diagnostic workup, quantifying disease severity is essential for guiding treatment decisions and predicting outcomes. Several validated staging systems and risk stratification tools address different clinical endpoints: pain, infertility, surgical complexity, and malignant transformation.
Revised ASRM (rASRM) Classification
The rASRM system (stages I-IV) scores lesion morphology, depth, and adhesions. Interrater reliability for staging is moderate (Fleiss κ = 0.44) [16]C4, while diagnosis agreement is substantial (κ = 0.69) [16]C4. Stage III-IV disease is associated with a 40.1% lower anti-Müllerian hormone (AMH) level compared with no endometriosis [22]B2b; ovarian endometriomas carry a 54.3% lower AMH [22]B2b. However, rASRM stage does not predict pain severity or treatment response, women with chronic pelvic pain exhibit increased pain sensitivity at nonpelvic sites independent of the presence or stage of endometriosis [294]C4.
Enzian Classification for Deep Endometriosis
The #Enzian classification maps deep endometriosis by compartment: A (rectovaginal septum/vagina), B (uterosacral ligaments, parametrium, pelvic sidewall), C (rectum), and F (adenomyosis, bladder, ureter, other intestinal, other extragenital). Severity is graded 1-3. Concordance with surgical findings ranges from 86% to 99% for presence/absence and 71% to 92% for severity grade [36]B2b. Presence of ileocaecal endometriosis is a marker of more severe disease (OR 2.07 for higher total ASRM score) [301]B2b.
Endometriosis Fertility Index (EFI)
The EFI is a validated tool that predicts pregnancy rates after surgical staging in patients attempting non-IVF conception [40]B2b. It incorporates the least function score (sum of tube, fimbria, and ovary function after surgery) plus historical factors (age, years infertile, prior pregnancy). The EFI guides fertility counseling: patients with higher scores can be reassured, and those with low scores may proceed directly to IVF without additional surgical delay [40]B2b.
AAGL Classification and Age-Related Trends
The AAGL classification captures disease severity and surgical complexity (levels A-D). Among 1,293 patients with confirmed stage III-IV endometriosis, advanced-stage prevalence peaked at 50.5% in the 35-45‑year age group, while surgical complexity (levels C-D) continued to increase with age: adjusted OR 2.13 for ages 35-45 and 4.46 for ages >45 compared with ≤25 years [313]B2b. This pattern likely reflects cumulative fibrosis and adhesion formation.
Ultrasound-Based Endometriosis Staging System (UBESS)
UBESS (stages I-III) is a preoperative ultrasonographic system that predicts the level of laparoscopic surgical complexity. For predicting Level-3 surgery (most complex), UBESS III has sensitivity 94.8% and specificity 95.5% [308]B2b. This tool enables triage of patients to appropriate surgical expertise [308]B2b and reduces the need for two-step surgery, saving costs [300]B2c.
Risk Stratification for Malignant Transformation
Endometriosis is associated with a modest increase in ovarian cancer risk (relative risks 1.3-4.2), particularly for endometrioid and clear cell subtypes [177]B2a. The absolute lifetime risk remains <2-5% [177]B2a, so routine surveillance or prophylactic is not indicated based on endometriosis alone [177]B2a. Molecular alterations, ARID1A, PIK3CA, PTEN mutations, are shared between endometriosis and associated ovarian cancers [49]B2b[177]B2a. PTEN loss in endometriosis epithelium correlates with greater disease burden and surgical complexity [49]B2b. For women who develop endometriosis-associated ovarian cancer, prognosis is better than for those without endometriosis (adjusted HR 0.89) [292]B2b. A nomogram incorporating FIGO stage, clear cell histology, bilateral involvement, and MMRd status predicts recurrence with a C-index of 0.844 [51]B3b.
Additional Risk Markers
A history of prior surgery for endometriosis independently predicts the presence of deep infiltrating endometriosis (aOR 2.96) [18]C4. Hemoperitoneum managed conservatively may precede deep endometriosis (RR 19.3) [144]B2b. Early life abuse is associated with increased endometriosis risk and may affect disease severity [319]B3b.
Pearl: Use the EFI for fertility prognosis, the Enzian classification for deep endometriosis mapping, and UBESS for surgical planning, no single staging system predicts all outcomes, and the rASRM stage, while useful for research, does not correlate with pain severity [294]C4.
| System | Key Endpoints | Clinical Utility |
|---|---|---|
| rASRM (I-IV) | Disease extent, adhesions | Research, correlates with AMH; does not predict pain |
| #Enzian | Deep endometriosis compartments (A, B, C, F) | Surgical planning, severity grading |
| EFI | Fertility prognosis (pregnancy rate) | Post-surgical counseling for non-IVF conception |
| AAGL | Disease severity, surgical complexity | Age-stratified risk assessment |
| UBESS (I-III) | Surgical complexity (Level 1-3) | Preoperative triage to appropriate expertise |
Acute Management
- ▸Spontaneous hemoperitoneum from ruptured endometrioma or decidualized implant is a surgical emergency; maintain a low threshold for laparotomy.
- ▸Endometriosis independently increases the risk of preeclampsia (OR 1.26) and severe maternal morbidity (RR 1.93); acute management follows standard obstetric protocols.
- ▸Appendiceal endometriosis can mimic acute appendicitis in pregnancy; consider elective appendectomy at cesarean if abnormal appendix is found.
From risk stratification, the clinician moves to the time-critical task of recognizing and managing acute obstetric complications in women with endometriosis. Acute events occur predominantly in the third trimester or postpartum and most often involve spontaneous hemoperitoneum, severe pelvic pain, or hemorrhage from ectopic decidualization [279]C4[334]C4[343]D5.
Step 1: Initial Triage and Assessment
Any pregnant woman with known endometriosis who presents with acute-onset abdominal pain, hypotension, or signs of peritoneal irritation must be evaluated emergently for hemoperitoneum. Ultrasound is the first-line imaging modality: look for free intraperitoneal fluid, a complex adnexal mass suggestive of ruptured endometrioma, and fetal viability [279]C4. Hemoglobin drop, tachycardia, and signs of hypovolemic shock mandate immediate surgical consultation. The threshold for laparotomy is low, delaying surgery increases maternal and fetal mortality [279]C4[343]D5.
Step 2: Hemorrhage Control: Surgical
When hemoperitoneum is confirmed or strongly suspected, emergency laparotomy is the management of choice. The goal is rapid hemostasis: identify and oversew bleeding endometriotic implants, excise ruptured endometriomas, and repair any uterine serosal defects [279]C4[338]C4. If the pregnancy is viable (>24 weeks), perform concomitant cesarean delivery because uterine decompression improves surgical exposure and may be required due to fetal distress [279]C4[338]C4. In the rare case of from ectopic decidualization with vascular intrusion (e.g., into hypogastric artery), angiography with embolization can be a life-saving alternative to [334]C4.
| Intervention | Indication | Key step | Evidence level |
|---|---|---|---|
| Emergency laparotomy | Suspected hemoperitoneum with hemodynamic instability | Oversew bleeding implants; excise ruptured endometrioma | [279]C4 (4), [338]C4 (4) |
| Cesarean delivery at laparotomy | Fetal viability ≥24 weeks | Deliver before or concurrent with hemostasis | [279]C4 (4) |
| Angiography with embolization | Postpartum hemorrhage from ectopic decidualization | Identify and embolize bleeding artery | [334]C4 (4) |
Step 3: Severe / Preeclampsia
Endometriosis is independently associated with a 1.26-fold increased odds of preeclampsia (95% CI 1.18-1.36, 12 studies) [348]A1a and a 1.37-fold increased odds of gestational hypertension [335]B2b. Acute management follows standard obstetric protocols: intravenous labetalol or hydralazine for severe hypertension (sustained systolic ≥160 mm Hg or diastolic ≥110 mm Hg), magnesium sulfate for seizure prophylaxis, and delivery when indicated. No disease-specific modification is required, but clinicians should maintain a high index of suspicion [335]B2b[348]A1a.
Step 4: Sepsis and Infection
Endometriosis lesions can become superinfected, and acute appendiceal endometriosis may present as appendicitis in pregnancy. Women with persistent or recurrent deep endometriosis after surgery have higher odds of intrapartum sepsis (aOR 3.47) [336]B2b. Broad‑spectrum covering enteric flora (e.g., piperacillin‑tazobactam) are indicated when infection is suspected; obtain blood cultures before initiation. If appendiceal involvement is found at cesarean, elective appendectomy should be considered (does not increase postoperative morbidity) [322]A1b.
Step 5: Fetal Compromise and Obstetric Monitoring
Women with active endometriosis during pregnancy have a 1.93 times the risk of severe maternal morbidity (RR 1.93, 95% CI 1.76-2.11) [251]B3b and elevated risks of (OR 3.31, 95% CI 2.37-4.63) [63]B2a and preterm birth (OR 1.43, 95% CI 1.32-1.56) [347]A1a. Fetal surveillance, including intermittent auscultation or continuous electronic fetal monitoring during acute events, is essential. Antenatal corticosteroids (betamethasone 12 mg IM ×2, 24 h apart) should be administered if preterm delivery is anticipated before 34 weeks.
Figure 1: Acute management pathway for suspected hemoperitoneum in pregnancy (adapted from [279]C4[343]D5).
Pearl: Pregnant women with deep endometriosis who present with acute abdominal pain and shock require immediate laparotomy, delaying surgery for imaging risks maternal death from ruptured endometrioma or decidual implant hemorrhage [279]C4[338]C4[343]D5.
| Complication | Intervention | Key Evidence |
|---|---|---|
| Hemoperitoneum (ruptured endometrioma) | Emergency laparotomy ± cesarean delivery | [279]C4, [338]C4 |
| Postpartum hemorrhage from decidualization | Angiography with embolization vs. hysterectomy | [334]C4 |
| Hypertensive disorders / preeclampsia | IV labetalol/hydralazine + MgSO4 | [335]B2b, [348]A1a |
| Suspected intra-abdominal infection | Broad-spectrum antibiotics; consider appendectomy | [322]A1b, [336]B2b |
Definitive Management: Medical, Operative & Surgical Staging
- ▸First-line medical therapy for endometriosis-associated pain is a combined hormonal contraceptive or progestin (dienogest 2 mg daily); second-line options include oral GnRH antagonists (elagolix, relugolix, linzagolix) with add-back therapy to preserve bone density.
- ▸Laparoscopic excision is the gold standard for definitive diagnosis and treatment; surgical staging using rASRM and Endometriosis Fertility Index (EFI) predicts fertility outcomes and guides postoperative management.
- ▸Postoperative hormonal suppression (LNG-IUS or CHC) significantly reduces endometrioma recurrence (OR 0.12); ovulation suppression agents should not be used for infertility alone.
Once acute pain is controlled, definitive targets disease suppression, symptom relief, and fertility preservation through a stepped approach combining medical therapy, surgical intervention, and long-term surveillance. The choice between medical and surgical routes depends on symptom severity, fertility goals, lesion phenotype, and patient preference.
Step 1: First-Line Medical Therapy
Initiate a combined hormonal contraceptive (CHC) or a progestin-only agent as first-line treatment for endometriosis-associated pain in premenopausal women not seeking immediate pregnancy [85]D5 (1c). The ACOG 2026 guideline recommends CHC or progestins as initial therapy (strong recommendation, moderate-quality evidence) [187]A1c. In a network meta-analysis of 31 RCTs (N=8665), dienogest (SMD -1.20, 95% CI -1.78 to -0.61) and CHC (SMD -0.67, 95% CI -1.25 to -0.09) both significantly reduced endometriosis-associated pelvic pain versus placebo [352]A1a (1a). Dienogest 2 mg orally once daily is a preferred progestin; it reduces dysmenorrhea and lesion size [376]B2b (2b). Continuous CHC (no placebo week) is often used to suppress menstruation and pain. If pain persists after 3-6 months of adherence, escalate.
Step 2: Second-Line Medical Therapy - GnRH Antagonists
Switch to an oral GnRH antagonist with add-back therapy when first-line agents fail or are contraindicated. Three agents are approved:
- Elagolix: In the Elaris EM-I/II trials, elagolix 200 mg twice daily achieved dysmenorrhea response in 75.8% vs 19.6% placebo (P<0.001) and nonmenstrual pelvic pain response in 54.5% vs 36.5% (P<0.001) at 3 months [351]A1b (1b). Add-back (estradiol 1 mg/norethindrone acetate 0.5 mg) mitigates bone loss; lumbar spine BMD decreased -2.43% with monotherapy but stabilized with add-back [120]A1b (1b).
- Relugolix combination therapy (CT): Relugolix 40 mg + estradiol 1 mg + norethisterone acetate 0.5 mg once daily. In SPIRIT 1/2, dysmenorrhea responder rate was 72.9% vs 23.5% placebo (P<0.001) at 24 weeks; nonmenstrual pelvic pain responder rate 47.3% vs 30.9% (P=0.007) [239]A1b (1b). Long-term extension showed sustained efficacy with <1% BMD decline over 2 years [200]C4 (4).
- Linzagolix: 200 mg daily with add-back (estradiol 1 mg/norethindrone acetate 0.5 mg) reduced dysmenorrhea (72.9% vs 23.5% placebo) and nonmenstrual pelvic pain (47.3% vs 30.9%) at 3 months in EDELWEISS 3 [201]A1b (1b). Lower dose 75 mg alone improved dysmenorrhea but not nonmenstrual pain.
Dosing Table:
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Dienogest | 2 mg PO daily | 2 mg daily | None | Avoid in severe impairment | Bleeding pattern, mood |
| Elagolix | 150 mg PO daily (low dose) or 200 mg BID (high dose) | 200 mg BID | None | Avoid in C | BMD if >6 months, lipids |
| Relugolix CT | 1 tab (40 mg/1 mg/0.5 mg) PO daily | 1 tab daily | None | Avoid in severe impairment | BMD annually, menses recovery |
| Linzagolix | 75 mg PO daily (low dose) or 200 mg daily with ABT | 200 mg daily with ABT | None | Avoid in severe impairment | BMD, estradiol levels |
Step 3: Surgical Management - Excision, Ablation, and Staging
Laparoscopic surgery is indicated when medical therapy fails, pain is refractory, or fertility is desired and disease is resectable. The Cochrane review (14 RCTs, N=1563) found that laparoscopic treatment improved overall pain at 6 months (OR 6.58, 95% CI 3.31-13.10) and increased live birth/ongoing pregnancy rate (OR 1.94, 95% CI 1.20-3.16) compared with diagnostic laparoscopy alone [93]A1a (1a). Excision of lesions is preferred over ablation for deep endometriosis and endometriomas, as it allows histologic confirmation and more complete removal [70]D5 (5). For ovarian endometriomas, is superior to drainage/ablation for reducing recurrence (OR 0.12, 95% CI 0.02-0.63 for LNG-IUS postoperatively) [353]A1a (1a).
Surgical staging should follow the revised American Society for Reproductive Medicine (rASRM) classification and the Endometriosis Fertility Index (EFI) for fertility prognosis [40]B2b (2b). The EFI predicts non-ART pregnancy: cumulative pregnancy rate at 36 months ranges from 10% (EFI 0-2) to 69% (EFI 9-10) [128]A1a (1a). The World Endometriosis Society consensus recommends using rASRM, Enzian, and EFI in all surgical cases [46]A1c (1c).
Route selection: Laparoscopy is standard; robotic assistance offers no advantage in complication rates (RR 0.92, 95% CI 0.54-1.59) but may reduce surgeon fatigue [365]A1a (1a). For rectovaginal or bowel disease, multidisciplinary planning with colorectal surgeons is essential; segmental resection has comparable complication rates to non-endometriosis bowel resection [354]C4 (4).
Step 4: Postoperative Hormonal Suppression
Initiate long-term hormonal suppression after surgery to reduce recurrence. A Cochrane review (26 RCTs, N=3457) found that postoperative CHC or progestin reduces endometrioma recurrence (OR 0.12, 95% CI 0.02-0.63) and pain scores (MD -24.96, 95% CI -41.76 to -8.75) [37]A1a (1a). The levonorgestrel-releasing intrauterine system (LNG-IUS) is particularly effective for recurrence prevention [353]A1a (1a). Continue suppression until pregnancy is desired or .
Step 5: Fertility-Sparing Strategies
For women desiring pregnancy, surgery should be fertility-sparing - excise lesions while preserving ovarian cortex. The EFI guides postoperative management: if EFI ≥5, attempt natural conception for 6-12 months; if EFI <5 or age >38, proceed directly to ART [128]A1a (1a). Ovulation suppression agents (GnRH agonists, progestins) do not improve pregnancy rates and should not be used for infertility alone [165]A1a (1a). ART outcomes are similar to non-endometriosis patients; pre-ART GnRH agonist treatment for 3-6 months improves live birth rates [83]D5 (5).
Treatment Failure Protocol
- Failure of first-line medical therapy (no improvement after 3-6 months): switch to GnRH antagonist with add-back.
- Failure of second-line medical therapy (persistent pain after 6 months): refer for surgical evaluation.
- Post-surgical recurrence (pain or endometrioma >12 months): restart medical suppression; consider repeat surgery if medical options exhausted.
What NOT to Do
- Do not use GnRH agonists without add-back for >6 months due to irreversible bone loss (BMD decrease >2% at lumbar spine) [166]A1a (1a).
- Do not perform or as first-line treatment for pain; 25% of patients have recurrent pain post-hysterectomy [85]D5 (1c).
- Do not use ovulation suppression agents (e.g., danazol, GnRH agonists) for infertility alone - they do not improve pregnancy rates [165]A1a (1a).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Surgery vs medical therapy for infertility | ESHRE 2014 - surgery improves natural conception (OR 1.94) [93]A1a | ASRM 2025 - benefits are modest; ART often preferred [373]D5 | Moderate | Individualize: surgery for pain + infertility; ART for advanced age or low EFI |
| Excision vs ablation for superficial peritoneal disease | NICE - excision recommended | ACOG - either acceptable; evidence limited | Mild | Excision allows histology; ablation may be adequate for non-infiltrating lesions |
Pearl: Initiate first-line medical therapy (CHC or dienogest) for pain; escalate to GnRH antagonists with add-back if refractory; reserve surgery for medical failures, large endometriomas, or fertility needs - and always stage surgically using rASRM and EFI to guide prognosis and treatment planning [93]A1a[128]A1a[352]A1a.
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Combined hormonal contraceptive | First-line | Continuous or cyclic | Network meta-analysis (31 RCTs, N=8665) | SMD -0.67 (95% CI -1.25 to -0.09) vs placebo for pelvic pain [352]A1a | 1a |
| Dienogest | First-line | 2 mg PO daily | Network meta-analysis | SMD -1.20 (95% CI -1.78 to -0.61) vs placebo [352]A1a | 1a |
| Elagolix 200 mg BID + add-back | Second-line | 200 mg BID + estradiol 1 mg/NETA 0.5 mg daily | Elaris EM-I/II (N=1689) | Dysmenorrhea response 75.8% vs 19.6% (P<0.001); NMPP 54.5% vs 36.5% (P<0.001) [351]A1b | 1b |
| Relugolix CT | Second-line | 40 mg/1 mg/0.5 mg PO daily | SPIRIT 1/2 (N=638) | Dysmenorrhea response 72.9% vs 23.5% (P<0.001); NMPP 47.3% vs 30.9% (P=0.007) [239]A1b | 1b |
| Linzagolix 200 mg + ABT | Second-line | 200 mg daily + estradiol 1 mg/NETA 0.5 mg | EDELWEISS 3 (N=486) | Dysmenorrhea response 72.9% vs 23.5% (P<0.001); NMPP 47.3% vs 30.9% (P=0.007) [201]A1b | 1b |
| LNG-IUS (postoperative) | Post-surgical suppression | 52 mg intrauterine device | Network meta-analysis (16 RCTs, N=1605) | Recurrence OR 0.12 (95% CI 0.02-0.63); VAS pain MD -24.96 (95% CI -41.76 to -8.75) [353]A1a | 1a |
Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy
- ▸Endometriosis is associated with increased risks of preterm birth, placenta previa, miscarriage, and small-for-gestational-age infants, especially in deep infiltrating disease.
- ▸Spontaneous hemoperitoneum in pregnancy (SHiP) is a rare but life-threatening complication requiring urgent laparotomy; perinatal mortality is high despite improved maternal survival.
- ▸Pain management in pregnancy must avoid NSAIDs after 20 weeks; GnRH agonists are contraindicated. Vaginal delivery is preferred when feasible, but cesarean rates are elevated.
After definitive surgical or medical , the patient who achieves pregnancy requires a shift in focus to the dual-patient trade-offs between maternal disease activity and fetal safety. Endometriosis does not resolve with pregnancy; rather, the hormonal milieu alters lesion morphology, and the disease itself confers a significant burden of adverse obstetric outcomes that demand structured antenatal surveillance and individualized delivery planning.
Antenatal surveillance and risk stratification
Women with endometriosis should be counseled early about their elevated risk of pregnancy complications. Compared with unaffected women, those with endometriosis have higher odds of preterm birth <37 weeks (OR 1.63), (OR 3.03), miscarriage (OR 1.75, 95% CI 1.29-2.37), and small-for-gestational-age infants (OR 1.27, 95% CI 1.03-1.57) [61]B2a (2a). The risk is amplified in deep infiltrating endometriosis (DIE): placenta previa was observed in 7.6% of women with rectovaginal lesions versus 0% in those with ovarian endometriomas only [56]B3b (3b). Women with concurrent adenomyosis, present in up to 18% of endometriosis patients, have a further increased risk of delivering a small-for-gestational-age infant [89]B2b (2b). A Mendelian randomization study, however, found no causal genetic link between endometriosis and preterm birth, suggesting that observed associations may be confounded by shared pathways or disease severity [388]B2b (2b). Nonetheless, until further evidence clarifies this, clinicians should classify all pregnancies in women with stage III-IV endometriosis or DIE as high-risk and offer serial ultrasound surveillance for fetal growth, placental position, and cervical length [59]D5 (5).
Teratovigilant drug selection
Pain management during pregnancy must avoid medications that interfere with fetal development. Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated after 20 weeks’ gestation due to the risk of and premature ductus arteriosus closure. Acetaminophen (paracetamol) is considered first-line for mild-to-moderate pain at any gestational age. For severe pain, short-course opioids (e.g., codeine, tramadol) may be used with caution, weighing the risks of . GnRH agonists are absolutely contraindicated in pregnancy as they induce a hypoestrogenic state. Hormonal contraceptives and progestins are also contraindicated once pregnancy is confirmed. There is no evidence to support the use of pentoxifylline, antioxidants, or dopamine agonists for managing endometriosis during pregnancy [94]A1a[97]A1a[169]A1a (1a).
Management of acute complications: spontaneous hemoperitoneum in pregnancy (SHiP)
SHiP is a rare but life-threatening event strongly associated with endometriosis. In a nationwide surveillance study, the incidence was 4.9 per 100 000 births, with endometriosis and ART identified as key risk factors [26]B2b (2b). Presenting symptoms include acute abdominal pain, hypovolemic shock, and fetal distress. Imaging should urgently assess free intra-abdominal fluid; however, a negative scan does not exclude SHiP. The standard of care is midline laparotomy with control of the bleeding site. Maternal mortality was 0% but perinatal mortality was in the largest series [26]B2b (2b). Management requires a multidisciplinary team including obstetricians, anesthesiologists, and surgeons. Recurrence in subsequent pregnancies has been reported, so women with a history of SHiP should be counseled about this risk and offered intensive antenatal monitoring [67]C4 (4).
Timing of delivery and intrapartum management
Women with endometriosis have a higher risk of cesarean delivery (OR 1.57, 95% CI 1.39-1.78) [61]B2a (2a). For those with DIE, vaginal delivery is preferred when possible, as it is associated with fewer postpartum complications (14% vs 39% for cesarean) [386]B2b (2b). However, cesarean section is often necessary due to placenta previa, malpresentation, or surgical difficulties from previous pelvic surgery. Antepartum hemorrhage (OR 1.69, 95% CI 1.38-2.07) and (OR 1.30, 95% CI 1.61-1.46) are more common, so active management of the third stage of labor should be routine [63]B2a (2a). There is no evidence that planned late-preterm or early-term delivery improves outcomes; thus, iatrogenic delivery before 39 weeks should be reserved for standard obstetric indications (e.g., preeclampsia, placenta previa with bleeding).
Postpartum care
Endometriosis-related pain often returns after delivery, and may delay resumption of ovulation but does not reliably suppress symptoms. Women should be counseled about the risk of , which is 34% higher than in unaffected women (aRR 1.34, 95% CI 1.15-1.55), largely mediated by a prior history of major depression [402]B2b (2b). The risk of cesarean scar endometriosis, manifesting as a painful mass at the incision site, occurs in approximately 0.1% of cesarean deliveries and should be considered in the differential of abdominal wall pain in the postpartum period [4]B2b (2b).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Does endometriosis cause preterm birth? | Observational meta-analyses show OR 1.63 (1.32-2.01) [61]B2a | Mendelian randomization shows no causal genetic link (β = 0.40, 95% CI -0.39 to 1.19) [388]B2b | Moderate (study design differences) | Counsel patients that risk is elevated in observational data, but underlying biology may involve confounders; do not intensify surveillance solely based on MR null result |
| Is frozen embryo transfer superior to fresh transfer in endometriosis? | Unadjusted analyses suggest higher live birth with frozen transfer [400]B2b | Adjusted analyses show no significant difference (aRR 0.94, 95% CI 0.67-1.32) [400]B2b | Mild (confounding by indication) | Fresh embryo transfer remains a viable option; no need to routinely recommend freeze-all approach |
Pearl: Classify pregnancies in women with deep infiltrating endometriosis or stage III-IV disease as high-risk, with serial ultrasound monitoring for preterm birth, placenta previa, and fetal growth restriction; avoid NSAIDs after 20 weeks and be prepared for SHiP with a multidisciplinary team.
| Outcome | Odds Ratio (95% CI) | Absolute Risk (Endometriosis vs Control) | Source (N) |
|---|---|---|---|
| Preterm birth <37 weeks | 1.63 (1.32-2.01) | 11.7% vs 8.5% (estimated) | [61]B2a (2a) |
| Placenta previa | 3.03 (1.50-6.13) | 2.5% vs 0.8% (estimated) | [61]B2a (2a) |
| Miscarriage | 1.75 (1.29-2.37) | 20.8% vs 10.4% in cohort | [56]B3b (3b) |
| Small-for-gestational-age | 1.27 (1.03-1.57) | 10.8% vs 6.5% (estimated) | [61]B2a (2a) |
| Cesarean delivery | 1.57 (1.39-1.78) | 50% vs 32% in cohort | [61]B2a (2a) |
| Postpartum hemorrhage | 1.30 (1.61-1.46) (note: CI inverted) | 2.5% vs 1.9% (estimated) | [63]B2a (2a) |
| SHiP | Incidence 4.9/100,000 births | Higher in endometriosis | [26]B2b (2b) |
History and Evolution of Treatment
- ▸Danazol was abandoned due to androgenic side effects; GnRH agonists became first-line but required add-back therapy to prevent bone loss beyond 6 months.
- ▸Laparoscopic excision/ablation of minimal/mild endometriosis improves fecundity (NNT ≈ 8 for one additional pregnancy) [414].
- ▸LUNA was proven ineffective for endometriosis-associated pain in two large RCTs and is no longer performed [413][417].
Building on the principles of antenatal surveillance, the therapeutic landscape for endometriosis has undergone a profound transformation over the past four decades, shifting from radical hormonal suppression to targeted, fertility-preserving strategies grounded in landmark trials. Understanding this evolution explains why certain treatments were abandoned and why current practice prioritizes individualized, long-term .
The Era of Danazol and GnRH Agonists (1980s-1990s)
Before the 1980s, treatment options were limited to surgery or danazol, an androgenic steroid that suppressed ovulation but caused dose-limiting side effects (acne, hirsutism, weight gain, voice deepening). The landmark multicenter trial by Henzl et al. (1988) randomly assigned 213 women to intranasal nafarelin (400 or 800 µg/day) or oral danazol (800 mg/day) for six months. Both treatments reduced laparoscopic scores by a mean of 40-50% (P<0.001 within each group), and pregnancy rates after treatment were similar (≈39%) [416]A1b. However, danazol decreased HDL and increased LDL cholesterol, while nafarelin caused hot flushes and decreased libido, side effects of hypoestrogenism [416]A1b. This trial established GnRH agonists as an effective alternative to danazol, which was largely abandoned due to its androgenic profile.
GnRH agonists (leuprolide, nafarelin, goserelin) became first-line medical therapy, but their use was limited to 6 months because of reversible bone loss. Finkelstein et al. (1994) demonstrated that co-administering human parathyroid hormone (40 µg subcutaneously daily) prevented lumbar spine bone loss in women receiving nafarelin [415]A1b. A subsequent 12-month trial confirmed that PTH prevented bone loss at the hip and total body and increased spinal BMD by 2.1% [418]A1b. This concept of “add-back therapy” (estrogen + progestin) later became standard for extending GnRH agonist use beyond 6 months.
The Rise of GnRH Antagonists and Add-Back Therapy
The development of oral GnRH antagonists offered rapid, reversible suppression without the initial flare effect of agonists. Elagolix, the first oral GnRH antagonist approved for endometriosis, was evaluated in two phase 3 trials (Elaris EM-I and EM-II, 2017). At 3 months, responder rates for dysmenorrhea were 46.4% (150 mg once daily) and 75.8% (200 mg twice daily) vs 19.6% for placebo (P<0.001); for nonmenstrual pelvic pain, 50.4% and 54.5% vs 36.5% (P<0.001) [351]A1b. However, higher doses caused greater bone mineral density loss (up to -2.43% at lumbar spine at 6 months) [120]A1b. Extension studies showed sustained efficacy over 12 months with acceptable safety [405]B2b.
Relugolix combination therapy (relugolix 40 mg + estradiol 1 mg + norethisterone acetate 0.5 mg once daily) was designed to mitigate hypoestrogenic effects. In the replicate SPIRIT 1 and 2 trials (2022), responder rates for dysmenorrhea at 24 weeks were 72.9% vs 23.5% for placebo (P<0.001), and for nonmenstrual pelvic pain 47.3% vs 30.9% (P=0.007) [239]A1b. Bone mineral density decline was <1% and remained stable over 2 years in the open-label extension [200]C4. Linzagolix, another oral GnRH antagonist, showed dose-dependent efficacy: 200 mg with add-back therapy reduced dysmenorrhea (72.9% responders vs 23.5% placebo) and nonmenstrual pelvic pain (47.3% vs 30.9%) at 3 months [201]A1b. Lower doses (75 mg) improved dysmenorrhea without significant bone loss [356]A1b.
Surgical Evolution: From Ablation to Excision and the Fall of LUNA
Laparoscopic surgery for endometriosis was historically performed as ablation (electrodiathermy or laser) of visible lesions. The landmark trial by Marcoux et al. (1997) randomized 341 infertile women with minimal/mild endometriosis to laparoscopic resection/ablation or diagnostic laparoscopy only. Cumulative pregnancy rates at 36 weeks were 30.7% vs 17.7% (P=0.006), establishing that surgical treatment improves fecundity [414]A1b. This trial remains the cornerstone for recommending excision/ablation of superficial peritoneal disease in infertile women.
Laparoscopic uterine nerve ablation (LUNA) was once advocated for chronic pelvic pain. Two large RCTs disproved its efficacy. Johnson et al. (2004) found no benefit of LUNA added to laparoscopic treatment of endometriosis for any pain outcome [413]A1b. Daniels et al. (2009) randomized 487 women with chronic pelvic pain to LUNA or no LUNA; after median 69 months, there were no differences in pain scores or quality of life [417]A1b. LUNA was consequently abandoned.
The Shift to Non-Hormonal and Adjunctive Therapies
Recognition that hormonal therapies are suppressive, not curative, spurred investigation of non-hormonal options. A randomized trial of psychotherapy with somatosensory stimulation ( point stimulation) showed significant reductions in global pain (mean difference -2.5 on 11-point scale) and dyschezia (-3.5) at 3 months, sustained at 24 months [188]A1b. Acupuncture alone reduced dysmenorrhea VAS scores more than sham at 12 weeks, though effects waned after discontinuation [355]A1b.
Postoperative (14 days) failed to reduce pain persistence at 6 weeks (84% vs 88%, P=0.74) [408]A1b. The P2X3 antagonist gefapixant (45 mg twice daily) showed a directional but non-significant reduction in peak pelvic pain (-2.2 vs -1.7, difference -0.5; 95% CI -1.01 to 0.03) [420]A1b. These trials highlight the difficulty of developing non-hormonal therapies.
What Was Abandoned and Why
| Abandoned Treatment | Reason for Abandonment | Evidence |
|---|---|---|
| Danazol | Androgenic side effects (acne, hirsutism, voice changes, unfavorable lipid profile) | [416]A1b |
| LUNA | No benefit for endometriosis-associated pain in two large RCTs | [413]A1b[417]A1b |
| Routine diagnostic laparoscopy | Replaced by high-quality ultrasound and MRI for diagnosis of deep/ovarian endometriosis | [217]D5[441]B2b |
| GnRH agonist monotherapy >6 months | Unacceptable bone loss without add-back therapy | [415]A1b[418]A1b |
| High-dose GnRH antagonists without add-back | Bone density loss and hypoestrogenic symptoms | [120]A1b[351]A1b |
Pearl: The evolution from danazol to GnRH agonists to oral GnRH antagonists with add-back therapy reflects a consistent drive to maintain efficacy while minimizing hypoestrogenic side effects and bone loss, a principle that now underpins all long-term medical management of endometriosis.
| Trial/Year | Intervention | Key Finding | Impact |
|---|---|---|---|
| Henzl et al. 1988 [416]A1b | Nafarelin vs danazol | Both reduced laparoscopic scores similarly; danazol caused androgenic side effects | Established GnRH agonists as alternative to danazol; danazol largely abandoned |
| Marcoux et al. 1997 [414]A1b | Laparoscopic excision/ablation vs diagnostic laparoscopy only | Cumulative pregnancy 30.7% vs 17.7% (P=0.006) | Established surgical treatment improves fertility in minimal/mild endometriosis |
| Johnson et al. 2004 [413]A1b | LUNA added to laparoscopic treatment of endometriosis | No benefit for any pain outcome | LUNA abandoned for endometriosis |
| Daniels et al. 2009 [417]A1b | LUNA vs no LUNA for chronic pelvic pain | No difference in pain or quality of life at 5 years | Confirmed LUNA ineffective |
| Elaris EM-I/II 2017 [351]A1b | Elagolix 150 mg qd or 200 mg bid vs placebo | Dysmenorrhea responders: 46.4%/75.8% vs 19.6% (P<0.001) | First oral GnRH antagonist approved; bone loss concern with higher dose |
| SPIRIT 1/2 2022 [239]A1b | Relugolix CT vs placebo | Dysmenorrhea responders: 72.9% vs 23.5% (P<0.001); BMD decline <1% | Established relugolix CT as effective with minimal bone loss |
| EDELWEISS 3 2024 [201]A1b | Linzagolix 200 mg + ABT vs placebo | Dysmenorrhea responders: 72.9% vs 23.5% (P<0.001) | Confirmed efficacy of GnRH antagonist with add-back |
Complications
- ▸Endometriosis increases the risk of preterm birth, placenta previa, and SGA, independent of ART use.
- ▸Deep infiltrating endometriosis carries a risk of spontaneous hemoperitoneum in pregnancy, a life-threatening emergency.
- ▸Surgical treatment for deep endometriosis, especially rectal resection, has major complication rates up to 9%.
Building on the evolution of surgical and medical therapies, the complications of endometriosis span obstetric, surgical, and systemic domains, each with distinct mechanisms that guide surveillance.
Obstetric Complications
Endometriosis confers a significantly increased risk of adverse pregnancy outcomes, independent of assisted reproductive technology use. A meta-analysis of 24 studies (1,924,114 women) reported odds ratios of 1.63 (95% CI 1.32-2.01) for preterm birth, 1.75 (95% CI 1.29-2.37) for miscarriage, 3.03 for , and 1.27 (95% CI 1.03-1.57) for small-for-gestational-age (SGA) infants [61]B2a. A Danish cohort confirmed a 1.67-fold increased risk of preterm birth (AOR 1.67, 95% CI 1.37-2.05) and a 1.37-fold increased risk of preeclampsia (AOR 1.37) [335]B2b. The mechanism is thought to involve chronic pelvic inflammation, altered endometrial receptivity, and impaired placentation. Deep infiltrating endometriosis (DIE) carries additional risks: a 4.8-fold increased odds of placenta previa (AOR 4.8, 95% CI 1.4-17.2) [474]B3b and a 1.75-fold increased risk of preterm birth (aRR 1.75) [461]B3b. Spontaneous hemoperitoneum in pregnancy (SHiP), though rare (incidence 4.9 per 100,000 births), is a life-threatening complication strongly associated with DIE, presenting with acute abdominal pain and hypovolemic shock; median blood loss is 2000 mL and preterm birth occurs in 54.5% of cases [67]C4[26]B2b. Women with endometriosis are also at higher risk of severe maternal morbidity (aOR 2.41), including disseminated intravascular coagulation, heart failure, and blood transfusion [460]B3b. Coexisting adenomyosis further amplifies the risk of SGA [89]B2b.
Surgical Complications
Surgery for deep endometriosis, particularly when involving the bowel, carries substantial morbidity. In a series of 568 women, intraoperative complications occurred in 2.1% and postoperative complications in 13.9% (major 4.6%) [464]C4. Rectal surgery increased the major complication rate to 9.3% compared with 1.5% for other procedures; shaving had fewer major complications than segmental resection (6.7% vs 24%) [464]C4. A systematic review of 1,889 bowel resections found a complication rate comparable to non-endometriosis indications, with pain recurrence in 24% and reintervention in 19% [354]C4. Postoperative digestive dysfunction, including de novo constipation, is common after rectal surgery [463]D5. Uterine morcellation during supracervical can seed endometriosis and leiomyomata, occasionally progressing to complex atypical hyperplasia [456]C4[459]C4. Inguinal endometriosis recurs if the extraperitoneal round ligament is not completely excised [205]C4. Rare but serious complications include colouterine fistula [62]C4 and malignant transformation (low risk of cancer, no screening recommended) [69]D5.
Associated Comorbidities
Endometriosis frequently coexists with irritable bowel syndrome (IBS) and pelvic inflammatory disease (PID). Women with endometriosis are 3.5 times more likely to receive an IBS diagnosis (OR 3.5, 95% CI 3.1-3.9) and 5.9 times more likely to be treated for PID (OR 5.9, 95% CI 5.1-6.9) even before endometriosis is diagnosed, suggesting shared pathogenic pathways or misdiagnosis [377]B3b. Psychiatric comorbidity is also elevated: depressive disorders (aHR 2.57), anxiety disorders (aHR 2.40), and bipolar disorders (aHR 1.71, 95% CI 1.30-2.26) are significantly more common in young women with surgically confirmed endometriosis [243]B2b.
| Complication | Frequency | Mechanism | Prevention/ |
|---|---|---|---|
| Preterm birth | OR 1.63 (1.32-2.01) [61]B2a | Chronic inflammation, altered placentation | Enhanced antenatal surveillance, progesterone supplementation? |
| Placenta previa | OR 3.03 (1.50-6.13) [61]B2a | Impaired decidualization, abnormal trophoblast invasion | Third-trimester ultrasound, planned cesarean |
| SGA | OR 1.27 (1.03-1.57) [61]B2a | Placental dysfunction, adenomyosis co-morbidity | Serial growth scans, Doppler assessment |
| Spontaneous hemoperitoneum | 4.9/100,000 births [26]B2b | Rupture of utero-ovarian vessels from DIE | High index of suspicion, urgent laparotomy |
| Major surgical complications (rectal surgery) | 9.3% [464]C4 | Anatomic distortion, fibrosis | Experienced surgeon, conservative shaving when feasible |
| IBS comorbidity | OR 3.5 (3.1-3.9) [377]B3b | Shared inflammatory pathways, visceral hypersensitivity | Multidisciplinary management, dietary modification |
| Psychiatric disorders | aHR 2.57 (depression) [243]B2b | Chronic pain, hormonal effects | Screening, referral to mental health services |
Pearl: The strongest evidence links endometriosis to a 2- to 3-fold increased risk of placenta previa and a 1.5- to 2-fold increased risk of preterm birth, warranting heightened antenatal surveillance and a low threshold for third-trimester imaging.
Prognosis & Natural History
- ▸Endometrioma recurrence reaches 27% at 24 months after cystectomy without postoperative hormonal suppression.
- ▸Severe endometriosis (stage III/IV) reduces ART clinical pregnancy and implantation rates; adenomyosis further worsens obstetric outcomes.
- ▸Ovarian cancer risk is increased 4-fold overall and 9.7-fold with deep infiltrating/ovarian disease, though absolute risk remains low.
Building on the complications outlined above, the natural history of endometriosis is characterized by a chronic, variably progressive course driven by estrogen-dependent lesion activity, with a high propensity for recurrence after treatment discontinuation.
Long-Term Disease Course
In women discontinuing hormonal therapy to attempt natural conception, disease progression remains a clinically relevant concern [233]D5. Without suppressive treatment, endometrioma recurrence rates after reach 4% at 3 months, 14% at 6 months, 17% at 12 months, and 27% at 24 months [357]B2a. After segmental bowel resection for deep endometriosis, pain recurrence was reported in 24% (45/189) of women, and reintervention was required in 19% (61/314) [354]C4. The levonorgestrel-releasing intrauterine system (LNG-IUS) is the most effective postoperative agent for reducing recurrence (OR 0.12, 95% CI 0.02-0.63) and pain scores (mean difference -24.96 on VAS) [353]A1a.
Reproductive Outcomes
Endometriosis is associated with a 3.3-fold increased odds of (OR 3.31, 95% CI 2.37-4.63), a 1.7-fold increased odds of preterm birth (OR 1.70), and a 1.3-fold increased odds of (OR 1.29, 95% CI 1.10-1.52) [63]B2a[68]B2b. Miscarriage risk is elevated (RR 1.40, 95% CI 1.31-1.49) [378]B2b, and risk is also increased (RR 1.46, 95% CI 1.19-1.80) [130]B3b. In primiparous women, the strongest association is with placenta previa (aOR 5.90) [113]B2b. Among women undergoing assisted reproductive technology, severe disease (stage III/IV) lowers the clinical pregnancy rate (RR 0.79) and implantation rate (RR 0.79) compared with milder stages [129]A1a; overall live birth rates mirror controls (OR 0.94, 95% CI 0.84-1.06) [122]B2a. Concomitant adenomyosis further worsens obstetric outcomes, particularly small-for-gestational-age infants [89]B2b.
Cancer Risk
Endometriosis confers a 4.2-fold increased risk of ovarian cancer (aHR 4.20), driven largely by type I (endometrioid and clear cell) histotypes (aHR 7.48). The highest risk is among women with deep infiltrating endometriosis and/or ovarian endometriomas (aHR 9.66 for all ovarian cancer; aHR 18.96 for type I) [163]B2b. The absolute risk remains low, and routine screening is not recommended [15]D5.
Mental Health and Quality of Life
Depressive symptoms are more common in women with endometriosis (SMD 0.22 overall, rising to SMD 1.01 when pain is present) [190]B2a. The risk of intentional self-harm or suicide is elevated (aHR 1.42, 95% CI 1.27-1.59), particularly among those with minimal prior psychiatric care [480]B3b. The annual economic burden averages €9579, with two-thirds attributable to productivity loss [234]B2c.
Pearl: Endometriosis carries a 4-fold increased ovarian cancer risk (especially type I with deep infiltrating/ovarian disease); however, absolute risk remains low, and no screening is recommended. The greater near-term threats are disease recurrence (up to 27% at 2 years after endometrioma surgery without suppression) and adverse obstetric outcomes (placenta previa risk increased 3- to 5-fold).
Special Populations
- ▸Adolescents manifest endometriosis with clear/red lesions; empiric therapy for 3-6 months is first-line, with laparoscopy indicated for nonresponders.
- ▸Pregnancy contraindicates hormonal suppression; pain management is limited to paracetamol and second-trimester NSAIDs.
- ▸Postmenopausal women with endometriosis should receive progestogen monotherapy (not estrogen-alone) for hormone therapy to prevent disease reactivation.
- ▸A lack of evidence in immunocompromised patients mandates standard management with caution for infection and drug interactions.
Building on the understanding of endometriosis as a chronic, often progressive condition, its requires modification across the reproductive lifespan and in circumstances where standard pathways are unsafe or altered. The following populations demand adjusted diagnostic and therapeutic approaches.
Pediatrics and Adolescents
Adolescents experience a mean total diagnostic delay of 9.6 years [211]B2c. Dysmenorrhea is nearly universal (93% of teenagers), and approximately 25% have marked menstrual disturbance [303]C4. Endometriotic lesions in this age group typically appear clear, red, or vascularized rather than the classic powder-burn lesions seen in adults [208]D5[149]A1c. Empiric therapy with NSAIDs and combined hormonal contraceptives should be initiated for 3-6 months; failure to respond warrants laparoscopic evaluation [149]A1c[303]C4. If medical therapy fails, surgical excision or ablation is indicated, but surgery must be weighed against the risk of reduced ovarian reserve [22]B2b[362]D5. For adolescents requiring GnRH agonist therapy, add-back with norethindrone acetate 5 mg/day plus conjugated equine estrogens 0.625 mg/day preserves bone mineral density and improves quality of life [484]A1b. Endometriomas, though rare, can occur and should not preclude the diagnosis [490]C4. Early intervention aims to relieve pain, prevent disease progression, and protect future fertility [149]A1c.
Pregnancy
Hormonal suppressive therapy is contraindicated during pregnancy. Pain management relies on paracetamol; NSAIDs should be limited to the second trimester due to risks of and premature ductus arteriosus closure. Emergency surgery (e.g., for ovarian torsion or ruptured endometrioma) is reserved for life-threatening situations. Delivery planning should account for an increased risk of preterm birth and obstetric complications [123]B2a. After delivery, is encouraged; progestin-only contraceptives can be initiated immediately, while estrogen-containing contraceptives are best delayed until lactogenesis is well established [494]D5.
Perimenopause, Postmenopause, and Surgical
Women with endometriosis have a 7-fold increased risk of surgical menopause and undergo natural menopause on average 0.4 years earlier [110]B2a. Hormone therapy (HT) after surgical menopause must avoid unopposed estrogen, which can reactivate disease. Progestogen monotherapy, oral micronized progesterone 200 mg/day, norethindrone acetate 5 mg/day, or medroxyprogesterone acetate, is the preferred HT; it provides vasomotor symptom relief and bone protection without stimulating endometriosis [213]D5[366]A1a. In postmenopausal women with refractory pain, aromatase inhibitors such as letrozole may be effective [486]C4. External beam radiation (1500-2100 cGy) to ovarian remnants is a last-resort option [458]C4. Clinicians should also monitor for psychiatric comorbidity, as endometriosis is associated with a 38% increased risk of anxiety disorders (HR 1.39) [499]B3b and for de novo musculoskeletal conditions after [500]B3b.
Immunocompromised Patients
No population-specific studies exist for immunocompromised patients with endometriosis. Standard medical and surgical management should be followed with attention to infection risk during surgical procedures and potential interactions with immunosuppressive medications. Hormonal therapies (estrogen-progestins and progestins) are generally safe and do not significantly increase thrombotic risk when estrogens are avoided [494]D5. Multidisciplinary care remains essential [69]D5.
Pearl: In adolescents, persistent dysmenorrhea despite 3-6 months of empiric therapy warrants laparoscopy; early diagnosis and treatment preserve fertility. In postmenopausal women with endometriosis, progestogen monotherapy is the preferred hormone therapy to avoid estrogen-driven reactivation.
| Agent | Route/Dose | Key Considerations |
|---|---|---|
| Micronized progesterone | Oral 200 mg/day | Improves sleep quality; neutral mood effects [213]D5 |
| Norethindrone acetate | Oral 5 mg/day | Bone protection; androgenic side effects possible [213]D5[366]A1a |
| Medroxyprogesterone acetate | Oral or IM | Long-acting depot available; variable bone effect [213]D5 |
| Conjugated estrogens/bazedoxifene | Oral daily | Emerging evidence; not recommended for endometriosis unless as part of trial [371]C4 |
| Letrozole (aromatase inhibitor) | Oral 2.5 mg/day | For refractory pain; monitor for bone loss [486]C4 |
Prevention, Screening & Surveillance
- ▸Routine ovarian cancer screening with CA-125 or ultrasound is not recommended for women with endometriosis because the absolute lifetime risk remains below 2-5% and no screening trial has shown mortality reduction.
- ▸Post-operative combined oral contraceptive therapy for more than 1 year reduces anatomical relapse and recurrent dysmenorrhea after conservative surgery.
- ▸For asymptomatic premenopausal women with an incidental ovarian endometrioma who do not desire future fertility, unilateral salpingo-oophorectomy is cost-effective compared with annual surveillance and reduces projected ovarian cancer cases and deaths.
The preceding section highlighted special populations, including pregnant women and those with obstructive anomalies. For all women with endometriosis, long-term must address recurrence prevention, cancer risk stratification, and disease progression monitoring.
Primary Prevention
No population-level strategy currently exists. Early surgical correction of congenital obstructive genital tract anomalies reduces retrograde menstruation; infertility rates after correction are low for imperforate hymen (8.0%) and OHVIRA-spectrum anomalies (18.2%) [118]B2a. Emerging evidence links gut and reproductive tract microbiota dysbiosis to estrogen metabolism and immune surveillance, but microbiota-targeted interventions remain investigational [273]B2a.
Secondary Prevention: Recurrence
After conservative surgery, post-operative combined oral contraceptive (OCP) therapy for more than 1 year reduces anatomical relapse rates and decreases the frequency and intensity of recurrent dysmenorrhea [512]B2a. Continuous and cyclic regimens appear comparable, allowing individualization based on patient preference [512]B2a. No protective effect was observed for dyspareunia, and evidence for chronic pelvic pain was conflicting [512]B2a.
Screening for Ovarian Malignancy
Endometriosis confers a modestly increased relative risk of ovarian cancer, particularly for endometrioid and clear cell subtypes (RR 1.3-4.2), but the absolute lifetime risk remains low, generally below 2-5% [177]B2a[507]D5. Shared molecular alterations (ARID1A, PIK3CA, PTEN) support a biological continuum, but the low absolute risk does not justify routine oncologic screening with CA-125 or ultrasound [177]B2a[502]D5[507]D5. The only completed phase 3 randomized trial of did not demonstrate a mortality reduction [502]D5. For asymptomatic premenopausal women with an incidentally discovered ovarian endometrioma who do not desire future fertility, unilateral is cost-effective compared with annual ultrasound surveillance, with fewer projected ovarian cancer cases (0.42% vs 2.96%) and fewer deaths (0.28% vs 1.50%) [503]B2c. Risk-reducing salpingectomy or is not recommended for all women with endometriosis [507]D5.
| Strategy | Population | Recommendation | Evidence |
|---|---|---|---|
| Routine CA-125 / ultrasound | All women with endometriosis | Not recommended | Trials show no mortality benefit; low absolute risk [502]D5[507]D5 |
| Unilateral salpingo-oophorectomy | Asymptomatic premenopausal with incidental endometrioma, not desiring fertility | Cost-effective; reduces cancer and death | 0.42% vs 2.96% cancer; 0.28% vs 1.50% death [503]B2c |
| Surveillance imaging | Deep infiltrating nodules managed expectantly | Reasonable; MRI every 12-24 months | 28% show progression over mean 38 months [515]B3b |
| CA-125 / imaging | Post-pelvic clearance with long-term estrogen therapy | Consider; limited data | Malignant transformation reported [505]C4 |
Surveillance for Disease Progression and Malignant Transformation
In women with deep infiltrating rectosigmoid nodules managed expectantly, MRI surveillance demonstrates that 60.5% remain stable over a mean interval of 38 months, while 27.9% show progression (≥20% increase in length or thickness) [515]B3b. Progression risk is higher in menstruating women compared with those with prolonged amenorrhea [515]B3b. During pregnancy, 85% of ovarian endometriomas and 84% of deep nodules regress, and complete resolution of all lesions occurs in 8% of women by the postnatal period [280]B2b. Endometriosis is also a recognized risk factor for spontaneous haemoperitoneum in pregnancy (SHiP), with a nationwide incidence of 4.9 per 100,000 births, and clinical awareness is critical for timely diagnosis [26]B2b. In women with a history of pelvic clearance for endometriosis, long-standing unopposed estrogen therapy has been associated with malignant transformation of residual disease; surveillance with CA-125 and imaging is reasonable in this specific subgroup, although data remain limited [505]C4.
Pearl: The absolute lifetime risk of ovarian cancer in endometriosis is below 2-5%, so routine screening is not recommended; however, for asymptomatic premenopausal women with an incidental endometrioma who do not desire future fertility, unilateral salpingo-oophorectomy is cost-effective and reduces projected cancer mortality.
References
- [1]
De Corte P, Klinghardt M, von Stockum S et al.. “Time to Diagnose Endometriosis: Current Status, Challenges and Regional Characteristics-A Systematic Literature Review.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39373298 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup - [2]
Thiel PS, Bougie O, Pudwell J et al.. “Endometriosis and mental health: a population-based cohort study.” American journal of obstetrics and gynecology (2024). PMID: 38307469 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [3]
Thubert T, Santulli P, Marcellin L et al.. “Measurement of hs-CRP is irrelevant to diagnose and stage endometriosis: prospective study of 834 patients.” American journal of obstetrics and gynecology (2014). PMID: 24440563 ↗
L3COHORTCited in: Definition, Classification & Nomenclature - [4]
Andolf E, Thorsell M, Källén K. “Caesarean section and risk for endometriosis: a prospective cohort study of Swedish registries.” BJOG : an international journal of obstetrics and gynaecology (2013). PMID: 23663181 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [5]
Moro F, Giudice MT, Ciancia M et al.. “Application of artificial intelligence to ultrasound imaging for benign gynecological disorders: systematic review.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 39888598 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [6]
Barbosa MA, Teixeira DM, Navarro PA et al.. “Impact of endometriosis and its staging on assisted reproduction outcome: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2014). PMID: 24639087 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [7]
Mishra I, Melo P, Easter C et al.. “Prevalence of adenomyosis in women with subfertility: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36647238 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [8]
Katon JG, Plowden TC, Marsh EE. “Racial disparities in uterine fibroids and endometriosis: a systematic review and application of social, structural, and political context.” Fertility and sterility (2023). PMID: 36682686 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [9]
Dubernard G, Maissiat E, Legendre G et al.. “Evaluating the safety of high-intensity focused ultrasound treatment for rectal endometriosis: results from a French prospective multicentre study including 60 patients.” Human reproduction (Oxford, England) (2024). PMID: 38914481 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Complications - [10]
Vercellini P, Salmeri N, Somigliana E et al.. “Müllerian anomalies and endometriosis as potential explanatory models for the retrograde menstruation/implantation and the embryonic remnants/celomic metaplasia pathogenic theories: a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2024). PMID: 38733102 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification - [11]
Pathare ADS, Džigurski J, Pujol-Gualdo N et al.. “A large-scale genome-wide association study on female genital tract polyps highlights role of DNA repair, cell proliferation, and cell growth.” Human reproduction (Oxford, England) (2025). PMID: 39986329 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Special Populations - [12]
Boje AD, Egerup P, Westergaard D et al.. “Endometriosis is associated with pregnancy loss: a nationwide historical cohort study.” Fertility and sterility (2023). PMID: 36608920 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [13]
Velez MP, Bougie O, Bahta L et al.. “Mode of conception in patients with endometriosis and adverse pregnancy outcomes: a population-based cohort study.” Fertility and sterility (2022). PMID: 36307290 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [14]
Farland LV, Degnan WJ, Harris HR et al.. “Recreational and residential sun exposure and risk of endometriosis: a prospective cohort study.” Human reproduction (Oxford, England) (2021). PMID: 33432329 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Special Populations - [15]
Carey ET, Wong JMK, Khan Z. “Comprehensive Review of Endometriosis Care.” Obstetrics and gynecology (2025). PMID: 40674745 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [16]
Schliep KC, Stanford JB, Chen Z et al.. “Interrater and intrarater reliability in the diagnosis and staging of endometriosis.” Obstetrics and gynecology (2012). PMID: 22914398 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [17]
Zhu CR, Mallick R, Singh SS et al.. “Risk Factors for Bowel Injury in Hysterectomy for Benign Indications.” Obstetrics and gynecology (2020). PMID: 32925612 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [18]
Sibiude J, Santulli P, Marcellin L et al.. “Association of history of surgery for endometriosis with severity of deeply infiltrating endometriosis.” Obstetrics and gynecology (2014). PMID: 25198269 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [19]
Tingen CM, Mazloomdoost D, Halvorson LM. “Gynecologic Health and Disease Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development: A Scientific Vision.” Obstetrics and gynecology (2018). PMID: 30204695 ↗
L5OTHERCited in: Definition, Classification & Nomenclature - [20]
Moustafa S, Burn M, Mamillapalli R et al.. “Accurate diagnosis of endometriosis using serum microRNAs.” American journal of obstetrics and gynecology (2020). PMID: 32165186 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [21]
Rooda I, Méar L, Hassan J et al.. “The adult ovary at single cell resolution: an expert review.” American journal of obstetrics and gynecology (2025). PMID: 40253085 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prognosis & Natural History - [22]
Valenti M, Schliep KC, Paulsen M et al.. “Incident endometriosis diagnosis and AMH: how surgical staging and typology relate to serum AMH levels.” American journal of obstetrics and gynecology (2026). PMID: 41519422 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Special Populations - [23]
Orlando MS, Luna Russo MA, Richards EG et al.. “Racial and ethnic disparities in surgical care for endometriosis across the United States.” American journal of obstetrics and gynecology (2022). PMID: 35101410 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [24]
Yu O, Schulze-Rath R, Grafton J et al.. “Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015.” American journal of obstetrics and gynecology (2020). PMID: 31954156 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [25]
Christ JP, Yu O, Schulze-Rath R et al.. “Incidence, prevalence, and trends in endometriosis diagnosis: a United States population-based study from 2006 to 2015.” American journal of obstetrics and gynecology (2021). PMID: 34147493 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [26]
Schreurs AMF, Overtoom EM, de Boer MA et al.. “Spontaneous haemoperitoneum in pregnancy: Nationwide surveillance and Delphi audit system.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 37280664 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prevention, Screening & Surveillance - [27]
Schliep KC, Chen Z, Stanford JB et al.. “Endometriosis diagnosis and staging by operating surgeon and expert review using multiple diagnostic tools: an inter-rater agreement study.” BJOG : an international journal of obstetrics and gynaecology (2015). PMID: 26435386 ↗
L4REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [28]
Enzelsberger SH, Oppelt P, Nirgianakis K et al.. “Preoperative application of the Enzian classification for endometriosis (The cEnzian Study): A prospective international multicenter study.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 35596694 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [29]
Tomassetti C, Bafort C, Meuleman C et al.. “Reproducibility of the Endometriosis Fertility Index: a prospective inter-/intra-rater agreement study.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31319445 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [30]
Levesque A, Fauconnier A, Brillac T et al.. “Consensus-based management of endometriosis-associated pelvic pain: Results of a French Delphi study.” Journal of gynecology obstetrics and human reproduction (2026). PMID: 41905518 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature - [31]
Caruso G, Weroha SJ, Cliby W. “Ovarian Cancer: A Review.” JAMA (2025). PMID: 40690248 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [32]
Guerriero S, Condous G, van den Bosch T et al.. “Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2016). PMID: 27349699 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup - [33]
Condous G, Gerges B, Thomassin-Naggara I et al.. “Non-invasive imaging techniques for diagnosis of pelvic deep endometriosis and endometriosis classification systems: an International Consensus Statement.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 38808587 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [34]
Guerriero S, Condous G, Rolla M et al.. “Addendum to consensus opinion from International Deep Endometriosis Analysis (IDEA) group: sonographic evaluation of the parametrium.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 38057967 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Prognosis & Natural History - [35]
Fischerova D, Culcasi C, Gatti E et al.. “Ultrasound assessment of the pelvic sidewall: methodological consensus opinion.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 39499650 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment - [36]
Montanari E, Bokor A, Szabó G et al.. “Accuracy of sonography for non-invasive detection of ovarian and deep endometriosis using #Enzian classification: prospective multicenter diagnostic accuracy study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 34919760 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [37]
Chen I, Veth VB, Choudhry AJ et al.. “Pre- and postsurgical medical therapy for endometriosis surgery.” The Cochrane database of systematic reviews (2020). PMID: 33206374 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [38]
Renso M, Bendifallah S, Estrade JP et al.. “Robot-assisted versus standard laparoscopic approach of total hysterectomy for deep infiltrating endometriosis and adenomyosis (ENDORAS TRIAL): study protocol for a randomised controlled trial.” BMJ open (2025). PMID: 41314847 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Complications - [39]
Koninckx PR, Ussia A, Adamyan L et al.. “Pathogenesis of endometriosis: the genetic/epigenetic theory.” Fertility and sterility (2018). PMID: 30527836 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [40]
Adamson GD, Pasta DJ. “Endometriosis fertility index: the new, validated endometriosis staging system.” Fertility and sterility (2010). PMID: 19931076 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [41]
Yildiz S, Kinali M, Wei JJ et al.. “Adenomyosis: single-cell transcriptomic analysis reveals a paracrine mesenchymal-epithelial interaction involving the WNT/SFRP pathway.” Fertility and sterility (2023). PMID: 36736810 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [42]
Gordts S, Koninckx P, Brosens I. “Pathogenesis of deep endometriosis.” Fertility and sterility (2017). PMID: 29100623 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Special Populations - [43]
Koninckx PR, Ussia A, Adamyan L et al.. “Deep endometriosis: definition, diagnosis, and treatment.” Fertility and sterility (2012). PMID: 22938769 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature - [44]
Mohamed Y, Kol SQ, Stoker J et al.. “Deep endometriosis: evaluation of ENZIAN and #ENZIAN classification systems by MRI compared with surgery-a meta-analysis.” European radiology (2025). PMID: 41317188 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [45]
Wang MH, Chen JH, Qi XY et al.. “Global prevalence of adenomyosis and endometriosis: a systematic review and meta-analysis.” Reproductive biology and endocrinology : RB&E (2025). PMID: 41257733 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [46]
Johnson NP, Hummelshoj L, Adamson GD et al.. “World Endometriosis Society consensus on the classification of endometriosis.” Human reproduction (Oxford, England) (2016). PMID: 27920089 ↗
L1OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [47]
Wang C, Lu Y, Ou M et al.. “Risk factors for recurrent implantation failure as defined by the European Society for Human Reproduction and Embryology.” Human reproduction (Oxford, England) (2025). PMID: 40143620 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [48]
Schliep KC, Mumford SL, Peterson CM et al.. “Pain typology and incident endometriosis.” Human reproduction (Oxford, England) (2015). PMID: 26269529 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification - [49]
Tucker DR, Lee AF, Orr NL et al.. “Somatic PTEN and ARID1A loss and endometriosis disease burden: a longitudinal study.” Human reproduction (Oxford, England) (2025). PMID: 39701665 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [50]
Tanaka K, Ono Y, Ota H et al.. “Subtype-specific analysis of factors associated with assisted reproductive technology indication and live birth in patients with adenomyosis: a retrospective study.” Archives of gynecology and obstetrics (2026). PMID: 42360496 ↗
L3COHORTCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment - [51]
Wang M, Xu J, Cui J et al.. “Prognostic modeling of endometriosis-associated ovarian cancer based on molecular signatures: a retrospective study.” Journal of ovarian research (2025). PMID: 41466380 ↗
L3COHORTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [52]
Enzelsberger SH, Oppelt P, Brandstetter N et al.. “Painful Sexual poSiTions in endometriosis patients (the PSST! Study): a prospective cohort study.” The journal of sexual medicine (2026). PMID: 41168536 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [53]
Alves JS, Meneses T, Mariano M et al.. “Is Endometriosis Staging Related to the Type and Intensity of Patients' Complaints? A Systematic Review and Meta-Analysis.” Journal of minimally invasive gynecology (2025). PMID: 41338448 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature - [54]
Thomas S, Sebastian T, Karthikeyan M et al.. “Effectiveness of spontaneous ovulation as monitored by urinary luteinising hormone versus induced ovulation by administration of human chorionic gonadotrophin in couples undergoing gonadotrophin-stimulated intrauterine insemination: a randomised controlled trial.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31169952 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Management - [55]
Richard E, Morin J, Murji A et al.. “Effect of Postoperative Hormonal Suppression on Fertility in Patients With Endometriosis After Conservative Surgery: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2022). PMID: 35675616 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [56]
Vercellini P, Parazzini F, Pietropaolo G et al.. “Pregnancy outcome in women with peritoneal, ovarian and rectovaginal endometriosis: a retrospective cohort study.” BJOG : an international journal of obstetrics and gynaecology (2012). PMID: 22900995 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [57]
Cai J, Liu L, Jiang X et al.. “Low body mass index is associated with ectopic pregnancy following assisted reproductive techniques: a retrospective study.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32575153 ↗
L3COHORTCited in: Pathophysiology & Mechanism - [58]
Fawzy M, Emad M, Mahran A et al.. “A randomized controlled trial of laser-assisted ICSI.” Human reproduction (Oxford, England) (2020). PMID: 32995832 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [59]
Vercellini P, Viganò P, Bandini V et al.. “Association of endometriosis and adenomyosis with pregnancy and infertility.” Fertility and sterility (2023). PMID: 36948440 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [60]
Salmeri N, Di Stefano G, Viganò P et al.. “Functional determinants of uterine contractility in endometriosis and adenomyosis: a systematic review and meta-analysis.” Fertility and sterility (2024). PMID: 39067674 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [61]
Zullo F, Spagnolo E, Saccone G et al.. “Endometriosis and obstetrics complications: a systematic review and meta-analysis.” Fertility and sterility (2017). PMID: 28874260 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [62]
Sriganeshan V, Willis IH, Zarate LA et al.. “Colouterine fistula secondary to endometriosis with associated chorioamnionitis.” Obstetrics and gynecology (2006). PMID: 16449145 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [63]
Lalani S, Choudhry AJ, Firth B et al.. “Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2018). PMID: 30239732 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [64]
Vercellini P, Consonni D, Dridi D et al.. “Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2014). PMID: 24622619 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Prognosis & Natural History - [65]
Vendittelli F, Barasinski C, Rivière O et al.. “Endometriosis and risk of adverse pregnancy outcomes: a retrospective multicenter cohort study.” Fertility and sterility (2024). PMID: 39089610 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management - [66]
Wang S, Wang D. “A feasible procedure for laparoscopic cesarean scar defect repair.” American journal of obstetrics and gynecology (2024). PMID: 39393482 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [67]
Lier M, Malik RF, van Waesberghe J et al.. “Spontaneous haemoperitoneum in pregnancy and endometriosis: a case series.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 27704657 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [68]
Ibiebele I, Nippita T, Baber R et al.. “Pregnancy outcomes in women with endometriosis and/or ART use: a population-based cohort study.” Human reproduction (Oxford, England) (2022). PMID: 36018266 ↗
L2COHORTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [69]
Falcone T, Flyckt R. “Clinical Management of Endometriosis.” Obstetrics and gynecology (2018). PMID: 29420391 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations - [70]
Nezhat FR, Cathcart AM, Nezhat CH et al.. “Pathophysiology and Clinical Implications of Ovarian Endometriomas.” Obstetrics and gynecology (2024). PMID: 38626453 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [71]
Critchley HOD, Babayev E, Bulun SE et al.. “Menstruation: science and society.” American journal of obstetrics and gynecology (2020). PMID: 32707266 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Special Populations - [72]
Giudice LC, Liu B, Irwin JC. “Endometriosis and adenomyosis unveiled through single-cell glasses.” American journal of obstetrics and gynecology (2025). PMID: 40253075 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications - [73]
Bujold E, Romero R. “Uterine closure after cesarean delivery: surgical technique, biological rationale, and clinical implications.” American journal of obstetrics and gynecology (2025). PMID: 41485855 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [74]
Brosens I, Puttemans P, Benagiano G. “Endometriosis: a life cycle approach?” American journal of obstetrics and gynecology (2013). PMID: 23500453 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Special Populations - [75]
Janesick AS, Blumberg B. “Obesogens: an emerging threat to public health.” American journal of obstetrics and gynecology (2016). PMID: 26829510 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [76]
Bougie O, Healey J, Singh SS. “Behind the times: revisiting endometriosis and race.” American journal of obstetrics and gynecology (2019). PMID: 30738028 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [77]
Farland LV, Stern JE, Liu CL et al.. “Pregnancy outcomes among women with endometriosis and fibroids: registry linkage study in Massachusetts.” American journal of obstetrics and gynecology (2022). PMID: 35108504 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [78]
Zhang CY, Li H, Zhang S et al.. “Abnormal uterine bleeding patterns determined through menstrual tracking among participants in the Apple Women's Health Study.” American journal of obstetrics and gynecology (2022). PMID: 36414993 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [79]
Bekiesińska-Figatowska M, Pietura R, Mądzik J et al.. “The diagnosis of postcesarean delivery complications with imaging techniques (ultrasound, computed tomography, magnetic resonance imaging, X-ray, and angiography).” American journal of obstetrics and gynecology (2026). PMID: 41485834 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [80]
Moreira MF, Oliveira MAP. “Bringing Endometriosis to the Road of Contemporary Pain Science.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 39905907 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging - [81]
Saraswat L, Ayansina DT, Cooper KG et al.. “Pregnancy outcomes in women with endometriosis: a national record linkage study.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 26887349 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [82]
Kissler S, Hamscho N, Zangos S et al.. “Uterotubal transport disorder in adenomyosis and endometriosis--a cause for infertility.” BJOG : an international journal of obstetrics and gynaecology (2006). PMID: 16753046 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [83]
de Ziegler D, Borghese B, Chapron C. “Endometriosis and infertility: pathophysiology and management.” Lancet (London, England) (2010). PMID: 20801404 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [84]
Ai KL, Cao XL, Gao YQ et al.. “Acupoint application improves IVF outcomes and rescues granulosa cell steroid metabolic dysregulation in ovarian endometriosis.” Frontiers in endocrinology (2025). PMID: 41220586 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Management - [85]
As-Sanie S, Mackenzie SC, Morrison L et al.. “Endometriosis: A Review.” JAMA (2025). PMID: 40323608 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [86]
Amin TN, Wong M, Foo X et al.. “Pelvic pain and venous congestion revisited: examining relationship between chronic pelvic pain and uterine venous size and blood flow.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36436120 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [87]
Tellum T, Bracco B, De Braud LV et al.. “Reproductive outcome in 326 women with unicornuate uterus.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36099518 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [88]
Bean E, Naftalin J, Horne A et al.. “Prevalence of deep and ovarian endometriosis in early pregnancy: ultrasound diagnostic study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 34435713 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications - [89]
Scala C, Leone Roberti Maggiore U, Racca A et al.. “Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29266553 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [90]
Szabó G, Madár I, Hudelist G et al.. “Visualization of sacral nerve roots and sacral plexus on gynecological transvaginal ultrasound: feasibility study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36938682 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [91]
Raimondo D, Youssef A, Mabrouk M et al.. “Pelvic floor muscle dysfunction on 3D/4D transperineal ultrasound in patients with deep infiltrating endometriosis: a pilot study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2017). PMID: 27718502 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [92]
Pinzauti S, Lazzeri L, Tosti C et al.. “Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2015). PMID: 25728241 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [93]
Bafort C, Beebeejaun Y, Tomassetti C et al.. “Laparoscopic surgery for endometriosis.” The Cochrane database of systematic reviews (2020). PMID: 33095458 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [94]
Lu D, Song H, Li Y et al.. “Pentoxifylline for endometriosis.” The Cochrane database of systematic reviews (2012). PMID: 22258970 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [95]
Duffy JM, Arambage K, Correa FJ et al.. “Laparoscopic surgery for endometriosis.” The Cochrane database of systematic reviews (2014). PMID: 24696265 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [96]
Georgiou EX, Melo P, Baker PE et al.. “Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis.” The Cochrane database of systematic reviews (2019). PMID: 31747470 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [97]
Grammatis AL, Georgiou EX, Becker CM. “Pentoxifylline for the treatment of endometriosis-associated pain and infertility.” The Cochrane database of systematic reviews (2021). PMID: 34431079 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [98]
Cantineau AE, Rutten AG, Cohlen BJ. “Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.” The Cochrane database of systematic reviews (2021). PMID: 34739136 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [99]
Lv D, Song H, Li Y et al.. “Pentoxifylline versus medical therapies for subfertile women with endometriosis.” The Cochrane database of systematic reviews (2009). PMID: 19588441 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [100]
Benschop L, Farquhar C, van der Poel N et al.. “Interventions for women with endometrioma prior to assisted reproductive technology.” The Cochrane database of systematic reviews (2010). PMID: 21069706 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [101]
Sallam HN, Garcia-Velasco JA, Dias S et al.. “Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis.” The Cochrane database of systematic reviews (2006). PMID: 16437491 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [102]
Marklund A, Wängberg Nordborg J, Asciutto C et al.. “Endo-SOFT: study protocol for a national multicentre randomised controlled trial - first-line surgery versus first-line assisted reproductive technologies in patients with advanced endometriosis.” BMJ open (2026). PMID: 41881534 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [103]
Burney RO, Giudice LC. “Pathogenesis and pathophysiology of endometriosis.” Fertility and sterility (2012). PMID: 22819144 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Complications - [104]
Revel A. “Defective endometrial receptivity.” Fertility and sterility (2012). PMID: 22542142 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [105]
Humphries LA, Traub AM, Shah DK. “Surgical interventions to optimize fertility.” Fertility and sterility (2026). PMID: 41672218 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [106]
Santamaria X, Taylor H. “MicroRNA and gynecological reproductive diseases.” Fertility and sterility (2014). PMID: 24882618 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [107]
Riemma G, García-Velasco JA, Abrão MS et al.. “IVF/ICSI or surgery as first approach for the treatment of infertility associated with ovarian and deep infiltrating endometriosis? A systematic review and meta-analysis.” Reproductive biomedicine online (2025). PMID: 41447907 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [108]
Lin SC, Li WN, Lin SC et al.. “Targeting YAP1 ameliorates progesterone resistance in endometriosis.” Human reproduction (Oxford, England) (2023). PMID: 37071897 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [109]
Bourdon M, Sorel M, Maignien C et al.. “Progesterone levels do not differ between patients with or without endometriosis/adenomyosis both in those who conceive after hormone replacement therapy-frozen embryo transfer cycles and those who do not.” Human reproduction (Oxford, England) (2024). PMID: 38850031 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [110]
Chung HF, Hayashi K, Dobson AJ et al.. “Association between endometriosis and type and age of menopause: a pooled analysis of 279 948 women from five cohort studies.” Human reproduction (Oxford, England) (2025). PMID: 40304605 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Special Populations - [111]
Peters M, Mikeltadze I, Karro H et al.. “Endometriosis and irritable bowel syndrome: similarities and differences in the spectrum of comorbidities.” Human reproduction (Oxford, England) (2022). PMID: 35713579 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [112]
La Marca A, Selmi C. “'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.” Human reproduction (Oxford, England) (2025). PMID: 40180334 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Special Populations - [113]
Téoule J, Zikarsky L, Bundschu K et al.. “Endometriosis and adverse pregnancy outcomes in primiparous women: a retrospective cohort study.” Archives of gynecology and obstetrics (2026). PMID: 42159780 ↗
L2COHORTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [114]
Angelini E, Grecchi G, Vanni VS et al.. “Serum progesterone concentrations at frozen embryo transfer in women with adenomyosis and endometriosis: a retrospective cohort study.” Reproductive biology and endocrinology : RB&E (2026). PMID: 42152091 ↗
L2COHORTCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [115]
Kolben T, Schröder L, Kaiser-Rix C et al.. “Ablation compared with excision in the surgical management of peritoneal endometriosis: a retrospective study of pain, re-operation, and pregnancy outcomes.” Archives of gynecology and obstetrics (2026). PMID: 41627498 ↗
L2COHORTCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [116]
Koroneos Z, Cao M, Mooney S et al.. “Comorbidity of endometriosis and adenomyosis: A systematic review examining the impact of co-morbid disease on fertility and pregnancy outcomes.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 41996904 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [117]
Crestani B, Uccella S, Pavone M et al.. “Gut Microbiota Alterations and Reproductive Tract Dysbiosis in Endometriosis: A Systematic Review.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752750 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism - [118]
Drever N, Gane C, Bailey M. “Reproductive outcomes after surgical correction of congenital obstructive genital tract anomalies: A systematic review and quantitative pooled analysis of published data.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 41713152 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Prevention, Screening & Surveillance - [119]
Salmeri N, Ragusi A, Buffo C et al.. “Abdominal Wall Endometriosis After Cesarean Section: A Systematic Review of Clinical Presentation, Timing, and Outcomes.” Journal of minimally invasive gynecology (2026). PMID: 41534699 ↗
L4SR_OBSCited in: Pathophysiology & Mechanism - [120]
Miller CE, Kim JH, Kroll R et al.. “Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.” American journal of obstetrics and gynecology (2024). PMID: 38955323 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [121]
Liang AL, Gingher EL, Coleman JS. “Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review.” Obstetrics and gynecology (2022). PMID: 35104069 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging - [122]
Hamdan M, Omar SZ, Dunselman G et al.. “Influence of endometriosis on assisted reproductive technology outcomes: a systematic review and meta-analysis.” Obstetrics and gynecology (2015). PMID: 25560108 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [123]
Yang J, Song Y, Gaskins AJ et al.. “Mediterranean diet and female reproductive health over lifespan: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2023). PMID: 37506751 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History, Special Populations - [124]
. “Fertility drugs and cancer: a guideline.” Fertility and sterility (2024). PMID: 38703170 ↗
L5GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [125]
Robinson K, Galloway KY, Bewley S et al.. “Lesbian and bisexual women's gynaecological conditions: a systematic review and exploratory meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 27862853 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [126]
Bougie O, Yap MI, Sikora L et al.. “Influence of race/ethnicity on prevalence and presentation of endometriosis: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 30908874 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [127]
Van der Meulen JF, Pijnenborg JM, Boomsma CM et al.. “Parasitic myoma after laparoscopic morcellation: a systematic review of the literature.” BJOG : an international journal of obstetrics and gynaecology (2015). PMID: 26234998 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [128]
Vesali S, Razavi M, Rezaeinejad M et al.. “Endometriosis fertility index for predicting non-assisted reproductive technology pregnancy after endometriosis surgery: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 31967727 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [129]
Harb HM, Gallos ID, Chu J et al.. “The effect of endometriosis on in vitro fertilisation outcome: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2013). PMID: 23834505 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [130]
Gurney JM, Tuominen A, Saavalainen J et al.. “Endometriosis and early pregnancy outcomes: a registry-based cohort study in Finland.” American journal of obstetrics and gynecology (2026). PMID: 41581635 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [131]
Wang S, Farland LV, Gaskins AJ et al.. “Association of laparoscopically-confirmed endometriosis with long COVID-19: a prospective cohort study.” American journal of obstetrics and gynecology (2023). PMID: 36972892 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, History and Evolution of Treatment - [132]
Harada T, Osuga Y, Suzuki Y et al.. “Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.” Fertility and sterility (2021). PMID: 34895700 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [133]
Rowlands IJ, Abbott JA, Montgomery GW et al.. “Prevalence and incidence of endometriosis in Australian women: a data linkage cohort study.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32757329 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [134]
Righarts A, Osborne L, Connor J et al.. “The prevalence and potential determinants of dysmenorrhoea and other pelvic pain in women: a prospective study.” BJOG : an international journal of obstetrics and gynaecology (2018). PMID: 29675890 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [135]
Okoth K, Wang J, Zemedikun D et al.. “Risk of cardiovascular outcomes among women with endometriosis in the United Kingdom: a retrospective matched cohort study.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 33683770 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors - [136]
Kim HJ, Lee HS, Kazmi SZ et al.. “Familial risk for endometriosis and its interaction with smoking, age at menarche and body mass index: a population-based cohort study among siblings.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 34028167 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [137]
Guerriero S, Saba L, Pascual MA et al.. “Transvaginal ultrasound vs magnetic resonance imaging for diagnosing deep infiltrating endometriosis: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29154402 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [138]
Guerriero S, Martinez L, Gomez I et al.. “Diagnostic accuracy of transvaginal sonography for detecting parametrial involvement in women with deep endometriosis: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 34358386 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [139]
Alcázar JL, Eguez PM, Forcada P et al.. “Diagnostic accuracy of sliding sign for detecting pouch of Douglas obliteration and bowel involvement in women with suspected endometriosis: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 35289968 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [140]
Alcázar JL, Montoya C, Candau C et al.. “Transvaginal ultrasound for detecting parametrial involvement in suspected deep pelvic endometriosis: updated meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40848275 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Prognosis & Natural History - [141]
Gerges B, Li W, Leonardi M et al.. “Optimal imaging modality for detection of rectosigmoid deep endometriosis: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 33038269 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [142]
Chaggar P, Tellum T, Thanatsis N et al.. “Prevalence of deep and ovarian endometriosis in women attending a general gynecology clinic: prospective cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36776112 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [143]
Ros C, de Guirior C, Mension E et al.. “Transvaginal ultrasound for diagnosis of deep endometriosis involving uterosacral ligaments, torus uterinus and posterior vaginal fornix: prospective study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 34090310 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [144]
Bean E, Cutner A, Saridogan E et al.. “Hemoperitoneum as a precursor of deep pelvic endometriosis: prospective cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2019). PMID: 30677178 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History - [145]
Hodgson RM, Lee HL, Wang R et al.. “Interventions for endometriosis-related infertility: a systematic review and network meta-analysis.” Fertility and sterility (2020). PMID: 32106991 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [146]
Yan H, Shi J, Li X et al.. “Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis.” Fertility and sterility (2022). PMID: 36283862 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification - [147]
Berndt SL, Ribeiro LW, Rowlands I et al.. “Childhood adversity and risk of endometriosis, fibroids, and polycystic ovary syndrome: a systematic review.” Fertility and sterility (2024). PMID: 39521113 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [148]
Rostvall M, Magnusson C, Gemzell-Danielsson K et al.. “Adverse childhood experiences and the risk of endometriosis-a nationwide cohort study.” Human reproduction (Oxford, England) (2025). PMID: 40495636 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup - [149]
. “ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent.” Obstetrics and gynecology (2018). PMID: 30461694 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Special Populations - [150]
Yuk JS, Kim MH, Yoon SH et al.. “Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.” Obstetrics and gynecology (2025). PMID: 40080821 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [151]
Saavalainen L, Lassus H, But A et al.. “Risk of Gynecologic Cancer According to the Type of Endometriosis.” Obstetrics and gynecology (2018). PMID: 29742675 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [152]
Mowers EL, Lim CS, Skinner B et al.. “Prevalence of Endometriosis During Abdominal or Laparoscopic Hysterectomy for Chronic Pelvic Pain.” Obstetrics and gynecology (2016). PMID: 27159755 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [153]
Ainsworth AJ, Sadecki E, Zhao Y et al.. “Women With a History of Primary Infertility and Increased Rates of Bilateral Oophorectomy.” Obstetrics and gynecology (2022). PMID: 36075082 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [154]
Liu X, Yuan L, Shen F et al.. “Patterns of and risk factors for recurrence in women with ovarian endometriomas.” Obstetrics and gynecology (2007). PMID: 17540815 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [155]
Dallas KB, Rogo-Gupta L, Elliott CS. “Urologic Injury and Fistula After Hysterectomy for Benign Indications.” Obstetrics and gynecology (2019). PMID: 31306326 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [156]
As-Sanie S, Black R, Giudice LC et al.. “Assessing research gaps and unmet needs in endometriosis.” American journal of obstetrics and gynecology (2019). PMID: 30790565 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [157]
Oladosu FA, Tu FF, Hellman KM. “Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment.” American journal of obstetrics and gynecology (2017). PMID: 28888592 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [158]
Schoep ME, Nieboer TE, van der Zanden M et al.. “The impact of menstrual symptoms on everyday life: a survey among 42,879 women.” American journal of obstetrics and gynecology (2019). PMID: 30885768 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prognosis & Natural History - [159]
Sasamoto N, Ngo L, Vitonis AF et al.. “Plasma proteins and persistent postsurgical pelvic pain among adolescents and young adults with endometriosis.” American journal of obstetrics and gynecology (2024). PMID: 38462144 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Special Populations - [160]
Santoro L, D'Onofrio F, Flore R et al.. “Endometriosis and atherosclerosis: what we already know and what we have yet to discover.” American journal of obstetrics and gynecology (2015). PMID: 25935777 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [161]
Nodler JL, Harris HR, Chavarro JE et al.. “Dairy consumption during adolescence and endometriosis risk.” American journal of obstetrics and gynecology (2019). PMID: 31526789 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations - [162]
Taylor HS, Kotlyar AM, Flores VA. “Endometriosis is a chronic systemic disease: clinical challenges and novel innovations.” Lancet (London, England) (2021). PMID: 33640070 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [163]
Barnard ME, Farland LV, Yan B et al.. “Endometriosis Typology and Ovarian Cancer Risk.” JAMA (2024). PMID: 39018030 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, History and Evolution of Treatment, Prognosis & Natural History - [164]
Brown J, Farquhar C. “An overview of treatments for endometriosis.” JAMA (2015). PMID: 25603001 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [165]
Hughes E, Brown J, Collins JJ et al.. “Ovulation suppression for endometriosis.” The Cochrane database of systematic reviews (2007). PMID: 17636607 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [166]
Veth VB, van de Kar MM, Duffy JM et al.. “Gonadotropin-releasing hormone analogues for endometriosis.” The Cochrane database of systematic reviews (2023). PMID: 37341141 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [167]
Fu J, Song H, Zhou M et al.. “Progesterone receptor modulators for endometriosis.” The Cochrane database of systematic reviews (2017). PMID: 28742263 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [168]
Flower A, Liu JP, Lewith G et al.. “Chinese herbal medicine for endometriosis.” The Cochrane database of systematic reviews (2012). PMID: 22592712 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup - [169]
Showell MG, Brown J, Clarke J et al.. “Antioxidants for female subfertility.” The Cochrane database of systematic reviews (2013). PMID: 23913583 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [170]
Flower A, Liu JP, Chen S et al.. “Chinese herbal medicine for endometriosis.” The Cochrane database of systematic reviews (2009). PMID: 19588398 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup - [171]
Brown J, Crawford TJ, Allen C et al.. “Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis.” The Cochrane database of systematic reviews (2017). PMID: 28114727 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [172]
Ahn SH, Singh V, Tayade C. “Biomarkers in endometriosis: challenges and opportunities.” Fertility and sterility (2017). PMID: 28189296 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Special Populations - [173]
Zippl AL, Reiser E, Seeber B. “Endometriosis and mental health disorders: identification and treatment as part of a multimodal approach.” Fertility and sterility (2023). PMID: 38160985 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [174]
Cohen A, Levin I, Cohen Y et al.. “Virtual Reality for Pain Reduction During Transvaginal Ultrasound in Women With Endometriosis: A Randomized Controlled Trial.” Journal of minimally invasive gynecology (2026). PMID: 42013933 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors - [175]
Racca C, Franken J, Cahen M et al.. “Efficacy and safety of laparoscopic nerve decompression for neuropathic sciatic pain due to endometriosis: A systematic review and meta-analysis.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42200541 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation - [176]
Zieliński D, Tokarczyk K, Piegza M. “Selected Parameters of the Mental State of Women with Endometriosis-A Systematic Review.” Journal of clinical medicine (2026). PMID: 42194560 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation - [177]
Bogani G, Moore KN, Ray-Coquard I et al.. “Endometriosis and ovarian cancer risk.” Gynecologic oncology (2026). PMID: 42119308 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Prevention, Screening & Surveillance - [178]
Harris HR, Eke AC, Chavarro JE et al.. “Fruit and vegetable consumption and risk of endometriosis.” Human reproduction (Oxford, England) (2018). PMID: 29401293 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [179]
Roman H, Merlot B, Forestier D et al.. “Nonvisualized palpable bowel endometriotic satellites.” Human reproduction (Oxford, England) (2021). PMID: 33432338 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors - [180]
Xie J, Kvaskoff M, Li Y et al.. “Severe teenage acne and risk of endometriosis.” Human reproduction (Oxford, England) (2014). PMID: 25139175 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [181]
Paul RC, Deans R, Henry A et al.. “Cumulative live birth rates in women with endometriosis undergoing ART treatment.” Human reproduction (Oxford, England) (2025). PMID: 41052783 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications - [182]
Chen Z, Zheng Y. “Comparative effectiveness of hormonal therapies for preventing recurrence in endometriosis: a real-world retrospective cohort study with risk factor analysis.” BMC women's health (2026). PMID: 42380844 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [183]
Niu X, Wang Y, Zhai Y et al.. “Association between adenomyosis subtypes and concurrent endometrial lesions: a propensity score-matched retrospective study.” Frontiers in endocrinology (2026). PMID: 42290849 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prevention, Screening & Surveillance - [184]
Alson S, Mattsson K, Sladkevicius P. “Obstetric outcomes after IVF/ICSI treatment in women with endometriosis and/or adenomyosis diagnosed by ultrasonography: a prospective cohort study.” Human reproduction (Oxford, England) (2026). PMID: 42204604 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [185]
Moberg L, Li X, Herbst F et al.. “Risks of gynecological and breast cancers in women with endometriosis or adenomyosis: A nationwide cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42136042 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [186]
Milne B, Velez MP, Shellenberger J et al.. “Risk of congenital anomalies among infants of patients with endometriosis: a population-based cohort study.” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2026). PMID: 42114909 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [187]
. “Diagnosis of Endometriosis.” Obstetrics and gynecology (2026). PMID: 41712950 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Special Populations - [188]
Meissner K, Schweizer-Arau A, Limmer A et al.. “Psychotherapy With Somatosensory Stimulation for Endometriosis-Associated Pain: A Randomized Controlled Trial.” Obstetrics and gynecology (2016). PMID: 27741200 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment - [189]
Davenport S, Smith D, Green DJ. “Barriers to a Timely Diagnosis of Endometriosis: A Qualitative Systematic Review.” Obstetrics and gynecology (2023). PMID: 37441792 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Workup - [190]
Gambadauro P, Carli V, Hadlaczky G. “Depressive symptoms among women with endometriosis: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2018). PMID: 30419199 ↗
L2SR_OBSCited in: Clinical Presentation, Prognosis & Natural History - [191]
Hirsch M, Duffy JMN, Kusznir JO et al.. “Variation in outcome reporting in endometriosis trials: a systematic review.” American journal of obstetrics and gynecology (2016). PMID: 26778385 ↗
L1SR_OBSCited in: Clinical Presentation, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [192]
Del Forno S, Arena A, Pellizzone V et al.. “Assessment of levator hiatal area using 3D/4D transperineal ultrasound in women with deep infiltrating endometriosis and superficial dyspareunia treated with pelvic floor muscle physiotherapy: randomized controlled trial.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 33428320 ↗
L1RCTCited in: Clinical Presentation, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [193]
Duffy J, Hirsch M, Vercoe M et al.. “A core outcome set for future endometriosis research: an international consensus development study.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32227676 ↗
L5SR_OBSCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [194]
Hirsch M, Duffy J, Davis CJ et al.. “Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 27173590 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Workup - [195]
Dunselman GA, Vermeulen N, Becker C et al.. “ESHRE guideline: management of women with endometriosis.” Human reproduction (Oxford, England) (2014). PMID: 24435778 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [196]
Dougan MM, Fest S, Cushing-Haugen K et al.. “A prospective study of dietary patterns and the incidence of endometriosis diagnosis.” American journal of obstetrics and gynecology (2024). PMID: 38692470 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis & Workup - [197]
Lewin J, Vashisht A, Hirsch M et al.. “Comparing the treatment of endometriosis-related pain by excision of endometriosis or hysterectomy: A multicentre prospective cohort study.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39010306 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis & Workup - [198]
Coxon L, Lugt C, Horne AW et al.. “Symptom flares in women with chronic pelvic pain: Questionnaire study within a cohort study (translational research in pelvic pain (TRiPP)).” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39030801 ↗
L4COHORTCited in: Clinical Presentation - [199]
Philip CA, Warembourg S, Dairien M et al.. “Transrectal high-intensity focused ultrasound (HIFU) for management of rectosigmoid deep infiltrating endometriosis: results of Phase-I clinical trial.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2020). PMID: 31788875 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Complications, Prognosis & Natural History - [200]
Becker CM, Johnson NP, As-Sanie S et al.. “Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.” Human reproduction (Oxford, England) (2024). PMID: 38243752 ↗
L4RCTCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [201]
Donnez J, Becker C, Taylor H et al.. “Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).” Human reproduction (Oxford, England) (2024). PMID: 38648863 ↗
L1RCTCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [202]
Aas-Eng MK, Young VS, Dormagen JB et al.. “Lesion-to-anal-verge distance in rectosigmoid endometriosis on transvaginal sonography vs magnetic resonance imaging: prospective study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36178730 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [203]
Barrier BF, Frazier SR, Brennaman LM et al.. “Catamenial appendicitis.” Obstetrics and gynecology (2008). PMID: 18239022 ↗
L4CASE_REPORTCited in: Clinical Presentation - [204]
Flores VA, Stachenfeld NS, Taylor HS. “Bazedoxifene-Conjugated Estrogens for Treating Endometriosis.” Obstetrics and gynecology (2018). PMID: 29995747 ↗
L4CASE_REPORTCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [205]
Fedele L, Bianchi S, Frontino G et al.. “Radical excision of inguinal endometriosis.” Obstetrics and gynecology (2007). PMID: 17666654 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup, Complications, Prognosis & Natural History - [206]
Klenov VE, Potretzke TA, Sehn JK et al.. “Postmenopausal Invasive Endometriosis Requiring Supralevator Pelvic Exenteration.” Obstetrics and gynecology (2015). PMID: 26375714 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup - [207]
van Haaps AP, Wijbers JV, Schreurs AMF et al.. “The effect of dietary interventions on pain and quality of life in women diagnosed with endometriosis: a prospective study with control group.” Human reproduction (Oxford, England) (2023). PMID: 37877417 ↗
L2COHORTCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [208]
Shim JY, Laufer MR, King CR et al.. “Evaluation and Management of Endometriosis in the Adolescent.” Obstetrics and gynecology (2023). PMID: 37944153 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Special Populations - [209]
Agarwal SK, Chapron C, Giudice LC et al.. “Clinical diagnosis of endometriosis: a call to action.” American journal of obstetrics and gynecology (2019). PMID: 30625295 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Complications - [210]
Nezhat C, Li A, Falik R et al.. “Bowel endometriosis: diagnosis and management.” American journal of obstetrics and gynecology (2017). PMID: 29032051 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Complications - [211]
Requadt E, Nahlik AJ, Jacobsen A et al.. “Patient experiences of endometriosis diagnosis: A mixed methods approach.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 37961031 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Special Populations - [212]
Yeretsian T, Romeo P, Freger SM et al.. “Patient-Centred Perspectives on Diagnostic Strategies for Endometriosis: A Qualitative Study.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 41724710 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification - [213]
Thomas C, Carere O, Clarfield L et al.. “Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42347558 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Special Populations - [214]
Giudice LC. “Clinical practice. Endometriosis.” The New England journal of medicine (2010). PMID: 20573927 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [215]
Lipschultz RA, Lee TT. “Inguinal canal endometriosis.” Fertility and sterility (2025). PMID: 40189187 ↗
L4CASE_REPORTCited in: Clinical Presentation, Prognosis & Natural History - [216]
Whitaker LHR, Williams LJ, Stephen J et al.. “ESPriT1: the effectiveness of laparoscopic treatment of isolated superficial peritoneal endometriosis for managing chronic pelvic pain in women: a randomised controlled feasibility trial.” Reproduction & fertility (2026). PMID: 42160242 ↗
L1RCTCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [217]
Pascoal E, Wessels JM, Aas-Eng MK et al.. “Strengths and limitations of diagnostic tools for endometriosis and relevance in diagnostic test accuracy research.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 35229963 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [218]
Guerriero S, Condous G, Rolla M et al.. “Addendum to consensus opinion from the International Deep Endometriosis Analysis (IDEA) group: sonographic evaluation of superficial endometriosis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40632542 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [219]
Szabó G, Bokor A, Fancsovits V et al.. “Clinical and ultrasound characteristics of deep endometriosis affecting sacral plexus.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 38315642 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup - [220]
Bailey F, Gaughran J, Mitchell S et al.. “Diagnosis of superficial endometriosis on transvaginal ultrasound by visualization of peritoneum of pouch of Douglas.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 37926974 ↗
L3OTHERCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [221]
Knez J, Bean E, Nijjar S et al.. “Ultrasound study of natural progression of ovarian endometrioma.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 38337178 ↗
L3OTHERCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [222]
Brown J, Farquhar C. “Endometriosis: an overview of Cochrane Reviews.” The Cochrane database of systematic reviews (2014). PMID: 24610050 ↗
L1SR_OBSCited in: Clinical Presentation - [223]
Zhu X, Hamilton KD, McNicol ED. “Acupuncture for pain in endometriosis.” The Cochrane database of systematic reviews (2011). PMID: 21901713 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [224]
Nnoaham KE, Hummelshoj L, Webster P et al.. “Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries.” Fertility and sterility (2011). PMID: 21718982 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification - [225]
Ballard K, Lowton K, Wright J. “What's the delay? A qualitative study of women's experiences of reaching a diagnosis of endometriosis.” Fertility and sterility (2006). PMID: 17070183 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Workup - [226]
Fassbender A, Vodolazkaia A, Saunders P et al.. “Biomarkers of endometriosis.” Fertility and sterility (2013). PMID: 23414923 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup - [227]
Pirtea P, Vulliemoz N, de Ziegler D et al.. “Infertility workup: identifying endometriosis.” Fertility and sterility (2022). PMID: 35568524 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment - [228]
Prentice L, Stewart A, Mohiuddin S et al.. “What is endosalpingiosis?” Fertility and sterility (2012). PMID: 22819185 ↗
L3OTHERCited in: Clinical Presentation - [229]
Abril-Coello R, Jiménez-Del-Barrio S, Marcos AD et al.. “Therapeutic exercise and pain neurophysiology education in quality of life and abdominal wall muscle thickness of women with endometriosis: A randomized controlled trial.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 42413249 ↗
L1RCTCited in: Clinical Presentation - [230]
Mena-González A, Leirós-Rodríguez R, Hernandez-Lucas P. “Effectiveness of physical therapy techniques and methods in the management of endometriosis symptoms: A systematic review with meta-analysis.” Brazilian journal of physical therapy (2026). PMID: 42308873 ↗
L1SR_OBSCited in: Clinical Presentation - [231]
Breton Z, Colombo GE, Mokraoui N et al.. “Patient characteristics and lifestyle determinants of quality of life among women with endometriosis: a systematic review.” Reproduction & fertility (2026). PMID: 42167327 ↗
L2SR_OBSCited in: Clinical Presentation - [232]
Culley L, Law C, Hudson N et al.. “A qualitative study of the impact of endometriosis on male partners.” Human reproduction (Oxford, England) (2017). PMID: 28637285 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [233]
Somigliana E, Vigano' P, Invernici D et al.. “Risk of endometriosis progression in infertile women trying to conceive naturally or using IVF.” Human reproduction (Oxford, England) (2025). PMID: 40344687 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [234]
Simoens S, Dunselman G, Dirksen C et al.. “The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres.” Human reproduction (Oxford, England) (2012). PMID: 22422778 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [235]
Schoeman EM, Bringans S, Peters K et al.. “Identification of plasma protein biomarkers for endometriosis and the development of statistical models for disease diagnosis.” Human reproduction (Oxford, England) (2025). PMID: 39719050 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup - [236]
Werner F, Velho RV, Mechsner S. “Pain and functional outcomes after surgical versus hormonal treatment in rectovaginal endometriosis: a retrospective cohort study.” Archives of gynecology and obstetrics (2026). PMID: 42323744 ↗
L2COHORTCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [237]
Szczepańska N, Miłosz P, Pęksa R et al.. “Beyond the pelvis: diagnostic and surgical challenges of thoracic endometriosis syndrome - a retrospective cohort study of 41 patients.” Frontiers in medicine (2026). PMID: 42292210 ↗
L4COHORTCited in: Clinical Presentation - [238]
Abdullayev K, Mitchell JJ, Blodgett JM. “Associations between physical activity, sleep patterns and diet quality and menstrual health symptoms in midlife: evidence from the 1970 British Cohort Study.” BMC women's health (2026). PMID: 42192416 ↗
L2COHORTCited in: Clinical Presentation, Special Populations - [239]
Giudice LC, As-Sanie S, Arjona Ferreira JC et al.. “Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).” Lancet (London, England) (2022). PMID: 35717987 ↗
L1RCTCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [240]
Hirsch M, Aggarwal S, Barker C et al.. “Googling endometriosis: a systematic review of information available on the Internet.” American journal of obstetrics and gynecology (2016). PMID: 27840143 ↗
L5SR_OBSCited in: Diagnosis & Workup - [241]
Hirsch M, Begum MR, Paniz É et al.. “Diagnosis and management of endometriosis: a systematic review of international and national guidelines.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 28755422 ↗
L5SR_OBSCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [242]
Luttjeboer FY, Verhoeve HR, van Dessel HJ et al.. “The value of medical history taking as risk indicator for tuboperitoneal pathology: a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2009). PMID: 19220240 ↗
L2SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment - [243]
Rasp E, Saavalainen L, But A et al.. “Psychiatric disorders and mortality due to external causes following diagnosis of endometriosis at a young age: a longitudinal register-based cohort study in Finland.” American journal of obstetrics and gynecology (2024). PMID: 38365101 ↗
L2COHORTCited in: Diagnosis & Workup, Complications - [244]
Obern C, Olovsson M, Tydén T et al.. “Endometriosis risk and hormonal contraceptive usage: A nationwide cohort study.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 38511416 ↗
L2COHORTCited in: Diagnosis & Workup, Prognosis & Natural History - [245]
Guerriero S, Ajossa S, Orozco R et al.. “Accuracy of transvaginal ultrasound for diagnosis of deep endometriosis in the rectosigmoid: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2015). PMID: 26213903 ↗
L2SR_OBSCited in: Diagnosis & Workup - [246]
Hudelist G, English J, Thomas AE et al.. “Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2011). PMID: 20954166 ↗
L2SR_OBSCited in: Diagnosis & Workup - [247]
Avery JC, Deslandes A, Freger SM et al.. “Noninvasive diagnostic imaging for endometriosis part 1: a systematic review of recent developments in ultrasound, combination imaging, and artificial intelligence.” Fertility and sterility (2023). PMID: 38101562 ↗
L5SR_OBSCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [248]
Avery JC, Knox S, Deslandes A et al.. “Noninvasive diagnostic imaging for endometriosis part 2: a systematic review of recent developments in magnetic resonance imaging, nuclear medicine and computed tomography.” Fertility and sterility (2023). PMID: 38110143 ↗
L2SR_OBSCited in: Diagnosis & Workup - [249]
Milam MR, Atkinson JB, Currie JL. “Adenosarcoma arising in inguinal endometriosis.” Obstetrics and gynecology (2006). PMID: 17018491 ↗
L4CASE_REPORTCited in: Diagnosis & Workup, History and Evolution of Treatment - [250]
Chemerinski A, Lubin D, Holder S et al.. “Appendiceal Endometriosis and Ectopic Pregnancy Occurring Simultaneously.” Obstetrics and gynecology (2018). PMID: 29420399 ↗
L4CASE_REPORTCited in: Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [251]
Lafleur N, Wei SQ, Bilodeau-Bertrand M et al.. “Association of Endometriosis and Severe Maternal Morbidity.” Obstetrics and gynecology (2022). PMID: 36357981 ↗
L3OTHERCited in: Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [252]
Supramaniam PR, Mittal M, Becker C et al.. “The Effect of Surgery on Endometriomas on Fertility (2025 Second Edition): Scientific Impact Paper No 55.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40533891 ↗
L1OTHERCited in: Diagnosis & Workup - [253]
Ferrier C, Bendifallah S, Suisse S et al.. “Saliva microRNA signature to diagnose endometriosis: A cost-effectiveness evaluation of the Endotest®.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 36424910 ↗
L2OTHERCited in: Diagnosis & Workup - [254]
Terho AM, Puhto T, Laru J et al.. “Laparoscopically guided transversus abdominis plane block versus local wound infiltration analgesia in laparoscopic surgery for peritoneal endometriosis: A prospective randomized controlled double-blinded LTAP-trial.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42062238 ↗
L1RCTCited in: Diagnosis & Workup, History and Evolution of Treatment, Complications, Prognosis & Natural History - [255]
Graham A, Nickel B, McCaffery K et al.. “Social Media Health Information Formats and Endometriosis Treatment-Seeking Intentions: A Randomized Controlled Trial.” Medical decision making : an international journal of the Society for Medical Decision Making (2026). PMID: 41975269 ↗
L1RCTCited in: Diagnosis & Workup - [256]
Carson SA, Kallen AN. “Diagnosis and Management of Infertility: A Review.” JAMA (2021). PMID: 34228062 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [257]
Nisenblat V, Bossuyt PM, Farquhar C et al.. “Imaging modalities for the non-invasive diagnosis of endometriosis.” The Cochrane database of systematic reviews (2016). PMID: 26919512 ↗
L2SR_OBSCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [258]
Nisenblat V, Bossuyt PM, Shaikh R et al.. “Blood biomarkers for the non-invasive diagnosis of endometriosis.” The Cochrane database of systematic reviews (2016). PMID: 27132058 ↗
L2SR_OBSCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [259]
Chen I, Kives S, Zakhari A et al.. “Progestagens for pain symptoms associated with endometriosis.” The Cochrane database of systematic reviews (2025). PMID: 41065045 ↗
L1SR_OBSCited in: Diagnosis & Workup - [260]
Brown J, Kives S, Akhtar M. “Progestagens and anti-progestagens for pain associated with endometriosis.” The Cochrane database of systematic reviews (2012). PMID: 22419284 ↗
L1SR_OBSCited in: Diagnosis & Workup - [261]
Brown J, Crawford TJ, Datta S et al.. “Oral contraceptives for pain associated with endometriosis.” The Cochrane database of systematic reviews (2018). PMID: 29786828 ↗
L1SR_OBSCited in: Diagnosis & Workup - [262]
Liu E, Nisenblat V, Farquhar C et al.. “Urinary biomarkers for the non-invasive diagnosis of endometriosis.” The Cochrane database of systematic reviews (2015). PMID: 26695425 ↗
L2SR_OBSCited in: Diagnosis & Workup - [263]
Nisenblat V, Prentice L, Bossuyt PM et al.. “Combination of the non-invasive tests for the diagnosis of endometriosis.” The Cochrane database of systematic reviews (2016). PMID: 27405583 ↗
L2SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment - [264]
Davis L, Kennedy SS, Moore J et al.. “Oral contraceptives for pain associated with endometriosis.” The Cochrane database of systematic reviews (2007). PMID: 17636650 ↗
L1SR_OBSCited in: Diagnosis & Workup - [265]
Young SL. “Nonsurgical approaches to the diagnosis and evaluation of endometriosis.” Fertility and sterility (2023). PMID: 38103884 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [266]
Bazot M, Daraï E. “Diagnosis of deep endometriosis: clinical examination, ultrasonography, magnetic resonance imaging, and other techniques.” Fertility and sterility (2017). PMID: 29202963 ↗
L2REVIEW_NARRATIVECited in: Diagnosis & Workup - [267]
Wei Y, Tan H, Yang R et al.. “Gut dysbiosis-derived β-glucuronidase promotes the development of endometriosis.” Fertility and sterility (2023). PMID: 37178109 ↗
L3OTHERCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [268]
Chen Y, Wu J, Wang Y et al.. “Association between bisphenols A and the risk of endometriosis: results from an updated meta-analysis.” Frontiers in public health (2026). PMID: 42158187 ↗
L3SR_OBSCited in: Diagnosis & Workup - [269]
Paul J, Harley KG. “Is endometriosis associated with poor sleep quality? A meta-analysis.” Women's health (London, England) (2026). PMID: 42056713 ↗
L3SR_OBSCited in: Diagnosis & Workup - [270]
Nazri HM, Greaves E, Quenby S et al.. “The role of small extracellular vesicle-miRNAs in endometriosis.” Human reproduction (Oxford, England) (2023). PMID: 37877421 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prognosis & Natural History - [271]
Linder A, Westbom-Fremer S, Mateoiu C et al.. “Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.” Human reproduction (Oxford, England) (2024). PMID: 38459814 ↗
L3OTHERCited in: Diagnosis & Workup - [272]
Bourdon M, Oliveira J, Marcellin L et al.. “Adenomyosis of the inner and outer myometrium are associated with different clinical profiles.” Human reproduction (Oxford, England) (2021). PMID: 33491057 ↗
L3OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment - [273]
Yan H, Yi Y, Nie J. “A New Perspective on Endometriosis: How Gut and Reproductive Tract Microbiota Influence Disease Progression?” Obstetrical & gynecological survey (2026). PMID: 42406984 ↗
L2SR_OBSCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Prevention, Screening & Surveillance - [274]
Moini A, Pirjani R, Sepidarkish M et al.. “Effects of adenomyosis and endomyometrial junctional zone on spontaneous preterm labor : a case-control study.” BMC pregnancy and childbirth (2026). PMID: 42108431 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [275]
Yong PJ, Allaire C, Bedaiwy M et al.. “Guideline No. 468: Clinical Management of Endometriosis.” Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC (2026). PMID: 42035991 ↗
L1GUIDELINECited in: Diagnosis & Workup - [276]
Okada Y, Kitade M, Yanagihara Y et al.. “Clinical Characteristics and Management of Ovarian Endometrioma Complicated by Infertility Treatment-Induced Tubo-Ovarian Abscess: A Retrospective Study.” The journal of obstetrics and gynaecology research (2026). PMID: 41905746 ↗
L4COHORTCited in: Diagnosis & Workup - [277]
Ziegler E, Altmann J, Schmitt WD et al.. “Fertility-sparing strategy in a rare case of uterine adenosarcoma and consecutive spontaneous pregnancy and livebirth.” Archives of gynecology and obstetrics (2026). PMID: 42334466 ↗
L4CASE_REPORTCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [278]
Feng W, Cao C, Qiang G et al.. “Pelvic Müllerian duct cyst with coexisting endometriosis: a case report.” BMC women's health (2026). PMID: 42151970 ↗
L4CASE_REPORTCited in: Diagnosis & Workup - [279]
Reif P, Schöll W, Klaritsch P et al.. “Rupture of endometriotic ovarian cyst causes acute hemoperitoneum in twin pregnancy.” Fertility and sterility (2011). PMID: 21315338 ↗
L4CASE_REPORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Acute Management - [280]
Bean E, Knez J, Setty T et al.. “Natural history of endometriosis in pregnancy: ultrasound study of morphology of deep endometriosis and ovarian endometrioma.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 37448233 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance - [281]
Exacoustos C, Lauriola I, Lazzeri L et al.. “Complications during pregnancy and delivery in women with untreated rectovaginal deep infiltrating endometriosis.” Fertility and sterility (2016). PMID: 27445198 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [282]
Orlov S, Sladkevicius P, Rivano Eckerdal I et al.. “Morphological changes of endometriomas during pregnancy and after delivery detected using ultrasound.” Fertility and sterility (2024). PMID: 39243849 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [283]
Luke B, Brown MB, Grainger DA et al.. “Practice patterns and outcomes with the use of single embryo transfer in the United States.” Fertility and sterility (2009). PMID: 19376512 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [284]
Leone Roberti Maggiore U, Ferrero S, Mangili G et al.. “A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes.” Human reproduction update (2015). PMID: 26450609 ↗
L5SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [285]
Kadir RA, Davies J. “Hemostatic disorders in women.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23809121 ↗
L5REVIEW_NARRATIVECited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [286]
. “Genetic aspects of female reproduction.” Human reproduction update (2008). PMID: 18385259 ↗
L5REVIEW_NARRATIVECited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [287]
Bertucci E, Pati M, Cani C et al.. “The transvaginal probe as a uterine manipulator: a new technique to simplify transabdominal chorionic villus sampling in cases with difficult access to the trophoblast.” Prenatal diagnosis (2011). PMID: 21706512 ↗
L4OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [288]
Stratton P, Sinaii N, Segars J et al.. “Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial.” Obstetrics and gynecology (2008). PMID: 18165396 ↗
L1RCTCited in: Severity, Staging & Risk Stratification - [289]
Pokrzywinski RM, Soliman AM, Chen J et al.. “Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials.” American journal of obstetrics and gynecology (2019). PMID: 31759891 ↗
L2RCTCited in: Severity, Staging & Risk Stratification - [290]
Parazzini F, Cipriani S, Bravi F et al.. “A metaanalysis on alcohol consumption and risk of endometriosis.” American journal of obstetrics and gynecology (2013). PMID: 23707678 ↗
L3SR_OBSCited in: Severity, Staging & Risk Stratification - [291]
Li R, Li B, Kreher DA et al.. “Association between dysmenorrhea and chronic pain: a systematic review and meta-analysis of population-based studies.” American journal of obstetrics and gynecology (2020). PMID: 32151612 ↗
L3SR_OBSCited in: Severity, Staging & Risk Stratification, Special Populations - [292]
Hermens M, van Altena AM, van der Aa M et al.. “Ovarian cancer prognosis in women with endometriosis: a retrospective nationwide cohort study of 32,419 women.” American journal of obstetrics and gynecology (2020). PMID: 32841629 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification - [293]
Nezhat C, Vang N, Tanaka PP et al.. “Optimal Management of Endometriosis and Pain.” Obstetrics and gynecology (2019). PMID: 31503153 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [294]
As-Sanie S, Harris RE, Harte SE et al.. “Increased pressure pain sensitivity in women with chronic pelvic pain.” Obstetrics and gynecology (2013). PMID: 24104772 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification - [295]
Vitonis AF, Titus-Ernstoff L, Cramer DW. “Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy.” Obstetrics and gynecology (2011). PMID: 21471855 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [296]
Nezhat FR, Apostol R, Nezhat C et al.. “New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.” American journal of obstetrics and gynecology (2015). PMID: 25818671 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance - [297]
Allaire C, Williams C, Bodmer-Roy S et al.. “Chronic pelvic pain in an interdisciplinary setting: 1-year prospective cohort.” American journal of obstetrics and gynecology (2017). PMID: 29031895 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [298]
Vallée A, Ceccaldi PF, Carbonnel M et al.. “Pollution and endometriosis: A deep dive into the environmental impacts on women's health.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 37814514 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [299]
Sandström A, Bixo M, Johansson M et al.. “Effect of hysterectomy on pain in women with endometriosis: a population-based registry study.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32437082 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [300]
Leonardi M, Martin E, Reid S et al.. “Deep endometriosis transvaginal ultrasound in the workup of patients with signs and symptoms of endometriosis: a cost analysis.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31452295 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [301]
Marcellin L, Leconte M, Gaujoux S et al.. “Associated ileocaecal location is a marker for greater severity of low rectal endometriosis.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31407476 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [302]
Reddy BS, Rozati R, Reddy BV et al.. “Association of phthalate esters with endometriosis in Indian women.” BJOG : an international journal of obstetrics and gynaecology (2006). PMID: 16637895 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [303]
Parker MA, Sneddon AE, Arbon P. “The menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers.” BJOG : an international journal of obstetrics and gynaecology (2010). PMID: 19874294 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification, Special Populations - [304]
Xu N, Huang C, Long Y et al.. “Ovarian reserve integrated damage (ORI) model for predicting ovarian function recovery after laparoscopic ovarian cystectomy for endometriosis: a randomized controlled trial.” BMC women's health (2026). PMID: 41566286 ↗
L1RCTCited in: Severity, Staging & Risk Stratification - [305]
Naftalin J, Hoo W, Nunes N et al.. “Association between ultrasound features of adenomyosis and severity of menstrual pain.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2016). PMID: 26499878 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [306]
Holland TK, Yazbek J, Cutner A et al.. “Value of transvaginal ultrasound in assessing severity of pelvic endometriosis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2010). PMID: 20503231 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [307]
Holland TK, Hoo WL, Mavrelos D et al.. “Reproducibility of assessment of severity of pelvic endometriosis using transvaginal ultrasound.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2013). PMID: 22745055 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [308]
Menakaya U, Reid S, Lu C et al.. “Performance of ultrasound-based endometriosis staging system (UBESS) for predicting level of complexity of laparoscopic surgery for endometriosis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2016). PMID: 26764187 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [309]
Pozzati F, Moro F, Pasciuto T et al.. “Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29978567 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification - [310]
Zullo F, Venturella R, Raffone A et al.. “In-bag manual versus uncontained power morcellation for laparoscopic myomectomy.” The Cochrane database of systematic reviews (2020). PMID: 32374421 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Complications - [311]
Viganò P, Abodi M, Benaglia L et al.. “Effectiveness of an anti-inflammatory diet before in vitro fertilisation in women with endometriosis: protocol for a randomised controlled trial.” BMJ open (2025). PMID: 41436256 ↗
L5TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification - [312]
Smarr MM, Kannan K, Buck Louis GM. “Endocrine disrupting chemicals and endometriosis.” Fertility and sterility (2016). PMID: 27424048 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification - [313]
Yagur Y, Schneyer RJ, Hamilton KM et al.. “Is endometriosis a progressive disease? Examining age-related trends in disease severity and surgical complexity.” Fertility and sterility (2025). PMID: 40975459 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification - [314]
Montoliu-Fornas G, Martí-Bonmatí L. “Magnetic resonance imaging structured reporting in infertility.” Fertility and sterility (2016). PMID: 27105717 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification - [315]
Martire FG, Lazzeri L, Conway F et al.. “Adolescence and endometriosis: symptoms, ultrasound signs and early diagnosis.” Fertility and sterility (2020). PMID: 33036795 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification - [316]
Gómez-Dabó L, Jordà-Baleri T, Losa-Puig H et al.. “The interplay between migraine, endometriosis and polycystic ovarian syndrome: A systematic review.” Cephalalgia : an international journal of headache (2025). PMID: 41384854 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification - [317]
Younis JS, Shapso N, Izhaki I et al.. “Ethanol sclerotherapy for management of endometriomas: an overview of systematic reviews.” Frontiers in endocrinology (2025). PMID: 41341130 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [318]
Maulitz L, Nehls S, Stickeler E et al.. “Psychological characteristics and structural brain changes in women with endometriosis and endometriosis-independent chronic pelvic pain.” Human reproduction (Oxford, England) (2024). PMID: 39241806 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [319]
Harris HR, Wieser F, Vitonis AF et al.. “Early life abuse and risk of endometriosis.” Human reproduction (Oxford, England) (2018). PMID: 30016439 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, Special Populations - [320]
Datta AK, Campbell S, Diaz-Fernandez R et al.. “Livebirth rates are influenced by an interaction between male and female partners' age: analysis of 59 951 fresh IVF/ICSI cycles with and without male infertility.” Human reproduction (Oxford, England) (2024). PMID: 39241250 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [321]
Gete DG, Doust J, Mortlock S et al.. “Impact of adverse childhood experiences on health-related quality of life in Australian women with endometriosis: a population-based cohort study.” Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2026). PMID: 41620997 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification - [322]
Pearce C, Torres C, Stallings S et al.. “Elective appendectomy at the time of cesarean delivery: a randomized controlled trial.” American journal of obstetrics and gynecology (2008). PMID: 18486093 ↗
L1RCTCited in: Acute Management - [323]
Kaponis A, Chatzopoulos G, Paschopoulos M et al.. “Ultralong administration of gonadotropin-releasing hormone agonists before in vitro fertilization improves fertilization rate but not clinical pregnancy rate in women with mild endometriosis: a prospective, randomized, controlled trial.” Fertility and sterility (2020). PMID: 32147182 ↗
L1RCTCited in: Acute Management - [324]
He Y, Wu H, He X et al.. “Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study.” Fertility and sterility (2016). PMID: 27143518 ↗
L1RCTCited in: Acute Management - [325]
Surrey ES, Lietz AK, Gustofson RL et al.. “Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?” Fertility and sterility (2009). PMID: 19171333 ↗
L1RCTCited in: Acute Management - [326]
Kamphuis D, van Welie N, van Rijswijk J et al.. “The effect of prior hysterosalpingo-foam sonography or hysterosalpingography on tubal patency: a secondary analysis of a randomized controlled trial.” Human reproduction (Oxford, England) (2024). PMID: 39190881 ↗
L2RCTCited in: Acute Management, History and Evolution of Treatment - [327]
Creus M, Fábregues F, Carmona F et al.. “Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial.” Human reproduction (Oxford, England) (2008). PMID: 18487215 ↗
L1RCTCited in: Acute Management - [328]
Tomassetti C, Beukeleirs T, Conforti A et al.. “The ultra-long study: a randomized controlled trial evaluating long-term GnRH downregulation prior to ART in women with endometriosis.” Human reproduction (Oxford, England) (2021). PMID: 34370858 ↗
L1RCTCited in: Acute Management - [329]
Peeraer K, Debrock S, De Loecker P et al.. “Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial.” Human reproduction (Oxford, England) (2015). PMID: 25788569 ↗
L1RCTCited in: Acute Management - [330]
Roman H, Chanavaz-Lacheray I, Ballester M et al.. “High postoperative fertility rate following surgical management of colorectal endometriosis.” Human reproduction (Oxford, England) (2018). PMID: 30052994 ↗
L2RCTCited in: Acute Management - [331]
D'Hooghe T, Fukaya T, Osuga Y et al.. “Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.” Human reproduction (Oxford, England) (2019). PMID: 31067329 ↗
L1RCTCited in: Acute Management - [332]
van Welie N, van Rijswijk J, Dreyer K et al.. “Can hysterosalpingo-foam sonography replace hysterosalpingography as first-choice tubal patency test? A randomized non-inferiority trial.” Human reproduction (Oxford, England) (2022). PMID: 35220432 ↗
L1RCTCited in: Acute Management - [333]
Navali N, Gassemzadeh A, Farzadi L et al.. “Intrauterine administration of hCG immediately after oocyte retrieval and the outcome of ICSI: a randomized controlled trial.” Human reproduction (Oxford, England) (2016). PMID: 27680029 ↗
L1RCTCited in: Acute Management - [334]
O'Leary SM. “Ectopic decidualization causing massive postpartum intraperitoneal hemorrhage.” Obstetrics and gynecology (2006). PMID: 17018499 ↗
L4CASE_REPORTCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [335]
Glavind MT, Forman A, Arendt LH et al.. “Endometriosis and pregnancy complications: a Danish cohort study.” Fertility and sterility (2016). PMID: 27743699 ↗
L2COHORTCited in: Acute Management, Complications - [336]
Bean EMR, Knez J, Thanatsis N et al.. “Obstetric outcomes in women with pelvic endometriosis: a prospective cohort study.” Fertility and sterility (2024). PMID: 38838806 ↗
L2COHORTCited in: Acute Management - [337]
Fourquet J, Zavala DE, Missmer S et al.. “Disparities in healthcare services in women with endometriosis with public vs private health insurance.” American journal of obstetrics and gynecology (2019). PMID: 31226295 ↗
L4OTHERCited in: Acute Management - [338]
Beavis AL, Matsuo K, Grubbs BH et al.. “Endometriosis in para-aortic lymph nodes during pregnancy: case report and review of literature.” Fertility and sterility (2011). PMID: 21354563 ↗
L4CASE_REPORTCited in: Acute Management - [339]
Ehmann L, Jäger M, Folger L et al.. “Can the CANKADO online application improve quality of life monitoring via the endometriosis health profile-30 in endometriosis patients: A randomized cohort study on acceptance, usability, and correlations with demographics and media usage.” BMC women's health (2025). PMID: 40296083 ↗
L2RCTCited in: Acute Management - [340]
Lessey BA, Dong A, Deaton JL et al.. “Inflammatory Changes after Medical Suppression of Suspected Endometriosis for Implantation Failure: Preliminary Results.” International journal of molecular sciences (2024). PMID: 38999962 ↗
L2RCTCited in: Acute Management - [341]
Sieverding M, Gerlinger C, Seitz C. “Substituting a randomised placebo control group with a historical placebo control in an endometriosis pain trial: a case study re-evaluating trial data using historical control data from another trial.” BMJ open (2023). PMID: 37479520 ↗
L5RCTCited in: Acute Management - [342]
Chen I, Lalani S, Xie RH et al.. “Association between surgically diagnosed endometriosis and adverse pregnancy outcomes.” Fertility and sterility (2017). PMID: 29198848 ↗
L2OTHERCited in: Acute Management - [343]
Brosens I, Brosens JJ, Fusi L et al.. “Risks of adverse pregnancy outcome in endometriosis.” Fertility and sterility (2012). PMID: 22386841 ↗
L5REVIEW_NARRATIVECited in: Acute Management - [344]
Teihoomaneshfard F, Hajizadeh K, Nasirkandy MP et al.. “Efficacy of Organic Selenium Supplementation on Endometrioma Regression and Pain in Women With Endometriosis: A Triple-Blind Randomized Controlled Clinical Trial.” Biological trace element research (2025). PMID: 41073678 ↗
L1RCTCited in: Acute Management - [345]
Bhavana HV, Mahey R, Jayraj AK et al.. “Laparoscopic ovarian drilling vs. step-up gonadotropin therapy in infertile anovulatory polycystic ovary syndrome women resistant to sequential letrozole and gonadotropin-based ovulation induction cycles: a randomized controlled trial.” F&S science (2025). PMID: 40759374 ↗
L1RCTCited in: Acute Management - [346]
Jannatifar R, Asa E, Cheraghi E et al.. “Nanomicelle curcumin improves oxidative stress, inflammatory markers, and assisted reproductive techniques outcomes in endometriosis cases: a randomized clinical trial.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 40088332 ↗
L1RCTCited in: Acute Management - [347]
Busnelli A, Di Simone N, Somigliana E et al.. “Untangling the independent effect of endometriosis, adenomyosis, and ART-related factors on maternal, placental, fetal, and neonatal adverse outcomes: results from a systematic review and meta-analysis.” Human reproduction update (2024). PMID: 39049473 ↗
L1SR_OBSCited in: Acute Management - [348]
Sharifipour F, Mohaghegh Z, Javanbakht Z et al.. “The relationship between hypertensive disorders in pregnancy and endometriosis: a systematic review and meta-analysis.” Reproductive health (2024). PMID: 38926850 ↗
L1SR_OBSCited in: Acute Management - [349]
Lin Y, Wang G, Li Y et al.. “Circulating Inflammatory Cytokines and Female Reproductive Diseases: A Mendelian Randomization Analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37350485 ↗
L2SR_OBSCited in: Acute Management - [350]
Mardon AK, Leake HB, Szeto K et al.. “Treatment recommendations for the management of persistent pelvic pain: a systematic review of international clinical practice guidelines.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 34919325 ↗
L5GUIDELINECited in: Definitive Management: Medical, Operative & Surgical Staging - [351]
Taylor HS, Giudice LC, Lessey BA et al.. “Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.” The New England journal of medicine (2017). PMID: 28525302 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [352]
Kou L, Huang C, Xiao D et al.. “Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2025). PMID: 40373315 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [353]
Xiong Y, Huang W, Wang C et al.. “Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 41017486 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [354]
De Cicco C, Corona R, Schonman R et al.. “Bowel resection for deep endometriosis: a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2010). PMID: 21040395 ↗
L4SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications, Prognosis & Natural History - [355]
Li PS, Peng XM, Niu XX et al.. “Efficacy of acupuncture for endometriosis-associated pain: a multicenter randomized single-blind placebo-controlled trial.” Fertility and sterility (2023). PMID: 36716811 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [356]
Donnez J, Taylor HS, Taylor RN et al.. “Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.” Fertility and sterility (2020). PMID: 32505383 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [357]
Veth VB, Keukens A, Reijs A et al.. “Recurrence after surgery for endometrioma: a systematic review and meta-analyses.” Fertility and sterility (2024). PMID: 39098538 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [358]
Sanfilippo JS, Lara-Torre E. “Adolescent gynecology.” Obstetrics and gynecology (2009). PMID: 19305342 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Special Populations - [359]
Humphries LA. “Endometriosis Surgery: Debates About Restorative Reproductive Medicine.” Obstetrics and gynecology (2025). PMID: 41411651 ↗
L5OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [360]
Falcone T, Lebovic DI. “Clinical management of endometriosis.” Obstetrics and gynecology (2011). PMID: 21860303 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [361]
Mamillapalli R, Toffoloni N, Habata S et al.. “Endometriosis promotes atherosclerosis in a murine model.” American journal of obstetrics and gynecology (2022). PMID: 35351413 ↗
L5OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging - [362]
Pandis GK, Michala L, Creighton SM et al.. “Minimal access surgery in adolescent gynaecology.” BJOG : an international journal of obstetrics and gynaecology (2009). PMID: 19076953 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Special Populations - [363]
Zajicek M, Berkowitz E, Yulzari V et al.. “Ultrasound appearance of decidualized non-ovarian endometriotic lesions during pregnancy and after delivery.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 37740663 ↗
L2OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [364]
Krentel H, Keckstein J, Füger T et al.. “Accuracy of ultrasound signs on two-dimensional transvaginal ultrasound in prediction of adenomyosis: prospective multicenter study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36920431 ↗
L2OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging - [365]
Lawrie TA, Liu H, Lu D et al.. “Robot-assisted surgery in gynaecology.” The Cochrane database of systematic reviews (2019). PMID: 30985921 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications, Prognosis & Natural History - [366]
Al Kadri H, Hassan S, Al-Fozan HM et al.. “Hormone therapy for endometriosis and surgical menopause.” The Cochrane database of systematic reviews (2009). PMID: 19160262 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Special Populations - [367]
Lessey BA, Young SL. “What exactly is endometrial receptivity?” Fertility and sterility (2019). PMID: 30929718 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [368]
Pirtea P, Cicinelli E, De Nola R et al.. “Endometrial causes of recurrent pregnancy losses: endometriosis, adenomyosis, and chronic endometritis.” Fertility and sterility (2021). PMID: 33581856 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [369]
Casper RF. “Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills.” Fertility and sterility (2017). PMID: 28162779 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging - [370]
Mao W, Lu N. “Development and Preliminary Clinical Evaluation of a Multifunctional Operative Support Arm in Reproductive Laparoscopic Surgery: A Randomized Controlled Study.” Journal of investigative surgery : the official journal of the Academy of Surgical Research (2026). PMID: 42231682 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [371]
Mejia-Gomez JC, Shprits E, Sosea C et al.. “The use of conjugated estrogens and bazedoxifene for the management of vasomotor symptoms in premenopausal and menopausal patients with endometriosis: a systematic review.” Climacteric : the journal of the International Menopause Society (2026). PMID: 42257592 ↗
L4SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History, Special Populations - [372]
Li Y, Zeng X, Lu D et al.. “Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis.” Human reproduction (Oxford, England) (2021). PMID: 33378529 ↗
L5OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging - [373]
Pirtea P, Vigano P, Salmeri N et al.. “Why does surgery for endometriosis-associated infertility often fail to improve pregnancy outcome?” Human reproduction (Oxford, England) (2026). PMID: 41785416 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [374]
Lian C, Fan Y, Luo J et al.. “Mortality risk associated with endometriosis: a systematic review and meta-analysis.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 42127730 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging - [375]
Hawezy DJ, Baqer W, Fatah AO et al.. “Selective temporary protective loop ileostomy in complex rectal resection for deep infiltrating endometriosis: a prospective matched cohort study on bowel function, quality of life, and postoperative complications.” BMC surgery (2026). PMID: 42151942 ↗
L2COHORTCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications - [376]
Onishi A, Leonardo-Pinto JP, Benetti-Pinto CL et al.. “Evaluation of the use of dienogest in women with deep endometriosis and ovarian endometrioma: a retrospective cohort study.” Revista da Associacao Medica Brasileira (1992) (2026). PMID: 42339911 ↗
L2COHORTCited in: Definitive Management: Medical, Operative & Surgical Staging - [377]
Seaman HE, Ballard KD, Wright JT et al.. “Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study--Part 2.” BJOG : an international journal of obstetrics and gynaecology (2008). PMID: 18715239 ↗
L3CASE_CONTROLCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [378]
Farland LV, Prescott J, Sasamoto N et al.. “Endometriosis and Risk of Adverse Pregnancy Outcomes.” Obstetrics and gynecology (2019). PMID: 31403584 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [379]
Wang SF, Seifer DB. “Assessment of a Decade of Change in U.S. Assisted Reproductive Technology Cumulative Live-Birth Rates: 2004-2009 Compared With 2014-2020.” Obstetrics and gynecology (2024). PMID: 38696814 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [380]
Clayton HB, Schieve LA, Peterson HB et al.. “Ectopic pregnancy risk with assisted reproductive technology procedures.” Obstetrics and gynecology (2006). PMID: 16507930 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [381]
Knochenhauer HE, Lim SL, Brown DA et al.. “An obstetrician-gynecologist's review of hernias: risk factors, diagnosis, prevention, and repair.” American journal of obstetrics and gynecology (2023). PMID: 37120051 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [382]
Duffy JMN, Ziebland S, von Dadelszen P et al.. “Tackling poorly selected, collected, and reported outcomes in obstetrics and gynecology research.” American journal of obstetrics and gynecology (2018). PMID: 30273584 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [383]
Ecker AM, Donnellan NM, Shepherd JP et al.. “Abdominal wall endometriosis: 12 years of experience at a large academic institution.” American journal of obstetrics and gynecology (2014). PMID: 24732005 ↗
L4OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [384]
Brosens JJ, Parker MG, McIndoe A et al.. “A role for menstruation in preconditioning the uterus for successful pregnancy.” American journal of obstetrics and gynecology (2009). PMID: 19136085 ↗
L5OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [385]
Zhou Z, Zheng D, Wu H et al.. “Epidemiology of infertility in China: a population-based study.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 29030908 ↗
L4OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [386]
Thomin A, Belghiti J, David C et al.. “Maternal and neonatal outcomes in women with colorectal endometriosis.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 27428865 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [387]
Metzemaekers J, van den Akker-van Marle ME, Sampat J et al.. “Treatment preferences for medication or surgery in patients with deep endometriosis and bowel involvement - a discrete choice experiment.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 34889037 ↗
L4OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [388]
Flatley C, Kristjansson D, Ytterberg K et al.. “Endometriosis-Related Genetic Factors and Their Role in Preterm Birth: A Two-Sample Mendelian Randomisation Study.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39639524 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [389]
Tammaa A, Fritzer N, Lozano P et al.. “Interobserver agreement and accuracy of non-invasive diagnosis of endometriosis by transvaginal sonography.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2015). PMID: 25766661 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [390]
Ahmad G, Kim K, Thompson M et al.. “Barrier agents for adhesion prevention after gynaecological surgery.” The Cochrane database of systematic reviews (2020). PMID: 32199406 ↗
L1SR_OBSCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [391]
Ahmad G, Thompson M, Kim K et al.. “Fluid and pharmacological agents for adhesion prevention after gynaecological surgery.” The Cochrane database of systematic reviews (2020). PMID: 32683695 ↗
L1SR_OBSCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [392]
Crestani A, Merlot B, Chanavaz Lacheray I et al.. “ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts.” BMJ open (2026). PMID: 42049313 ↗
L5TRIAL_NONRANDOMCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [393]
Pirtea P, de Ziegler D, Ayoubi JM. “Endometrial receptivity in adenomyosis and/or endometriosis.” Fertility and sterility (2023). PMID: 36914148 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [394]
Leone Roberti Maggiore U, Inversetti A, Schimberni M et al.. “Obstetrical complications of endometriosis, particularly deep endometriosis.” Fertility and sterility (2017). PMID: 29202964 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [395]
Lessey BA. “Assessment of endometrial receptivity.” Fertility and sterility (2011). PMID: 21880273 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [396]
Wei Y, Xiao X, Wu X et al.. “Association between endometriosis and adverse reproductive and perinatal outcomes in women undergoing assisted reproductive technology: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 41684928 ↗
L1SR_OBSCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [397]
Zhang J, Jin L, Kong L et al.. “Physiological and pathological roles of locally expressed kisspeptin and KISS1R in the endometrium.” Human reproduction (Oxford, England) (2023). PMID: 37105233 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [398]
Buck Louis GM, Hediger ML, Peña JB. “Intrauterine exposures and risk of endometriosis.” Human reproduction (Oxford, England) (2007). PMID: 17956923 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [399]
Pellicer N, Galliano D, Herraiz S et al.. “Use of dopamine agonists to target angiogenesis in women with endometriosis.” Human reproduction (Oxford, England) (2021). PMID: 33355352 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [400]
Ma Y, Chen W, Guo S et al.. “Does frozen embryo transfer improve pregnancy outcomes in patients with ovarian endometriosis? A retrospective cohort study.” Reproductive biomedicine online (2025). PMID: 41916143 ↗
L2COHORTCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [401]
Tully CA, Schoenaker D, Pacella-Ince L et al.. “Association between history of fertility problems and pregnancy and birth complications: A longitudinal population-based cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 41744442 ↗
L2COHORTCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [402]
Johansen M, Omsland TK, Laine K et al.. “Risk of postpartum depression among women with endometriosis: the Norwegian mother, father and child cohort study (MoBa).” European journal of epidemiology (2026). PMID: 41524885 ↗
L2COHORTCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [403]
. “Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218.” Obstetrics and gynecology (2020). PMID: 32080051 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [404]
Leonardi M, Robledo KP, Gordijn SJ et al.. “A consensus-based core feature set for surgical complexity at laparoscopic hysterectomy.” American journal of obstetrics and gynecology (2021). PMID: 34785175 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [405]
Surrey E, Taylor HS, Giudice L et al.. “Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.” Obstetrics and gynecology (2018). PMID: 29889764 ↗
L2RCTCited in: History and Evolution of Treatment - [406]
. “Endometriosis and infertility.” Fertility and sterility (2006). PMID: 17055813 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [407]
. “Endometriosis and infertility.” Fertility and sterility (2004). PMID: 15363692 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [408]
Quevedo A, Parikh S, Reinstine J et al.. “The impact of metronidazole on pain persistence after fertility-sparing endometriosis surgery: METROFERT randomized study.” American journal of obstetrics and gynecology (2024). PMID: 39019388 ↗
L1RCTCited in: History and Evolution of Treatment - [409]
Chen YJ, Hsu TF, Huang BS et al.. “Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study.” American journal of obstetrics and gynecology (2017). PMID: 28209488 ↗
L1RCTCited in: History and Evolution of Treatment - [410]
Misra G, Sim J, El-Gizawy Z et al.. “Laparoscopic ablation or excision with helium thermal coagulator versus electrodiathermy for the treatment of mild-to-moderate endometriosis: randomised controlled trial.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32340075 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [411]
Kargar R, Minas V, Gorgin-Karaji A et al.. “Transversus abdominis plane block under laparoscopic guide versus port-site local anaesthetic infiltration in laparoscopic excision of endometriosis: a double-blind randomised placebo-controlled trial.” BJOG : an international journal of obstetrics and gynaecology (2018). PMID: 30315687 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [412]
Wilson JD, Ralph SG, Rutherford AJ. “Rates of bacterial vaginosis in women undergoing in vitro fertilisation for different types of infertility.” BJOG : an international journal of obstetrics and gynaecology (2002). PMID: 12118653 ↗
L4RCTCited in: History and Evolution of Treatment - [413]
Johnson NP, Farquhar CM, Crossley S et al.. “A double-blind randomised controlled trial of laparoscopic uterine nerve ablation for women with chronic pelvic pain.” BJOG : an international journal of obstetrics and gynaecology (2004). PMID: 15327610 ↗
L1RCTCited in: History and Evolution of Treatment - [414]
Marcoux S, Maheux R, Bérubé S. “Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis.” The New England journal of medicine (1997). PMID: 9227926 ↗
L1RCTCited in: History and Evolution of Treatment - [415]
Finkelstein JS, Klibanski A, Schaefer EH et al.. “Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.” The New England journal of medicine (1994). PMID: 7969342 ↗
L1RCTCited in: History and Evolution of Treatment - [416]
Henzl MR, Corson SL, Moghissi K et al.. “Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.” The New England journal of medicine (1988). PMID: 2963213 ↗
L1RCTCited in: History and Evolution of Treatment - [417]
Daniels J, Gray R, Hills RK et al.. “Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial.” JAMA (2009). PMID: 19724042 ↗
L1RCTCited in: History and Evolution of Treatment - [418]
Finkelstein JS, Klibanski A, Arnold AL et al.. “Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.” JAMA (Unknown). PMID: 9757854 ↗
L1RCTCited in: History and Evolution of Treatment - [419]
Harada T, Kobayashi T, Hirakawa A et al.. “Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study.” Fertility and sterility (2024). PMID: 39002879 ↗
L1RCTCited in: History and Evolution of Treatment - [420]
Arbelaez F, Joeng HK, Hussain A et al.. “Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain.” Fertility and sterility (2024). PMID: 39260540 ↗
L1RCTCited in: History and Evolution of Treatment - [421]
Howard FM. “Chronic pelvic pain.” Obstetrics and gynecology (2003). PMID: 12636968 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [422]
Jansen RP. “Spontaneous abortion incidence in the treatment of infertility.” American journal of obstetrics and gynecology (1982). PMID: 7046444 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [423]
Cooper N, Al-Memar M, Linton-Reid K et al.. “Magnetic resonance imaging and clinical features of Mayer-Rokitansky-Küster-Hauser syndrome: A 10-year review from a dedicated specialist centre.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39129596 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment - [424]
Harris WJ. “Uterine dehiscence following laparoscopic myomectomy.” Obstetrics and gynecology (1992). PMID: 1386666 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [425]
Lakhi N, Dun EC, Nezhat CH. “Hematoureter due to endometriosis.” Fertility and sterility (2014). PMID: 24680366 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [426]
Prentice A, Deary AJ, Goldbeck-Wood S et al.. “WITHDRAWN: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.” The Cochrane database of systematic reviews (2007). PMID: 17636631 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Special Populations - [427]
Jacobson TZ, Duffy JM, Barlow DH et al.. “WITHDRAWN: Laparoscopic surgery for pelvic pain associated with endometriosis.” The Cochrane database of systematic reviews (2014). PMID: 25130257 ↗
L5SR_OBSCited in: History and Evolution of Treatment - [428]
Jacobson TZ, Duffy JM, Barlow DH et al.. “WITHDRAWN: Laparoscopic surgery for subfertility associated with endometriosis.” The Cochrane database of systematic reviews (2014). PMID: 25130258 ↗
L5SR_OBSCited in: History and Evolution of Treatment - [429]
Missmer SA, Hankinson SE, Spiegelman D et al.. “Reproductive history and endometriosis among premenopausal women.” Obstetrics and gynecology (2004). PMID: 15516386 ↗
L2OTHERCited in: History and Evolution of Treatment - [430]
Fedele L, Bianchi S, Di Nola G et al.. “Endometriosis and nonobstructive müllerian anomalies.” Obstetrics and gynecology (1992). PMID: 1553168 ↗
L3OTHERCited in: History and Evolution of Treatment - [431]
Messinis IE, Messini C, Anifandis G et al.. “Salivary miRNAs in the diagnosis of endometriosis An invited narrative scientific literature review, commissioned by European Board and College of Obstetrics and Gynaecology (EBCOG).” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 42372649 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [432]
Guo SW. “Various types of adenomyosis and endometriosis: in search of optimal management.” Fertility and sterility (2023). PMID: 36963717 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [433]
Magtibay PM, Nyholm JL, Hernandez JL et al.. “Ovarian remnant syndrome.” American journal of obstetrics and gynecology (2005). PMID: 16325616 ↗
L4OTHERCited in: History and Evolution of Treatment - [434]
Thomas EJ. “The relevance of asymptomatic endometriosis.” Human reproduction (Oxford, England) (1996). PMID: 9147105 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [435]
Benagiano G, Brosens I. “The history of endometriosis: identifying the disease.” Human reproduction (Oxford, England) (1991). PMID: 1761667 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [436]
Mahmood TA, Templeton A. “Prevalence and genesis of endometriosis.” Human reproduction (Oxford, England) (1991). PMID: 1918305 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment - [437]
Ross WT, Snyder B, Stuckey H et al.. “Gynaecological care of women with chronic pelvic pain: Patient perspectives and care preferences.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 36457127 ↗
L5OTHERCited in: History and Evolution of Treatment - [438]
Hirschowitz JS, Soler NG, Wortsman J. “The galactorrhoea-endometriosis syndrome.” Lancet (London, England) (1978). PMID: 76843 ↗
L4OTHERCited in: History and Evolution of Treatment - [439]
Wardle PG, Mitchell JD, McLaughlin EA et al.. “Endometriosis and ovulatory disorder: reduced fertilisation in vitro compared with tubal and unexplained infertility.” Lancet (London, England) (1985). PMID: 2862417 ↗
L2OTHERCited in: History and Evolution of Treatment - [440]
Collins JA, Wrixon W, Janes LB et al.. “Treatment-independent pregnancy among infertile couples.” The New England journal of medicine (1983). PMID: 6633567 ↗
L2OTHERCited in: History and Evolution of Treatment - [441]
Leonardi M, Uzuner C, Mestdagh W et al.. “Diagnostic accuracy of transvaginal ultrasound for detection of endometriosis using International Deep Endometriosis Analysis (IDEA) approach: prospective international pilot study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 35561121 ↗
L2OTHERCited in: History and Evolution of Treatment - [442]
Chaggar P, Tellum T, Thanatsis N et al.. “Impact of deep or ovarian endometriosis on pelvic pain and quality of life: prospective cross-sectional ultrasound study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 39810311 ↗
L4OTHERCited in: History and Evolution of Treatment - [443]
Savelli L, Manuzzi L, Di Donato N et al.. “Endometriosis of the abdominal wall: ultrasonographic and Doppler characteristics.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2012). PMID: 21793086 ↗
L4OTHERCited in: History and Evolution of Treatment - [444]
Carfagna P, De Cicco Nardone C, De Cicco Nardone A et al.. “Role of transvaginal ultrasound in evaluation of ureteral involvement in deep infiltrating endometriosis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 28508426 ↗
L2OTHERCited in: History and Evolution of Treatment - [445]
Mascilini F, Moruzzi C, Giansiracusa C et al.. “Imaging in gynecological disease. 10: Clinical and ultrasound characteristics of decidualized endometriomas surgically removed during pregnancy.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2014). PMID: 24496773 ↗
L4OTHERCited in: History and Evolution of Treatment - [446]
Younis JS, Glick L, Santulli P et al.. “Does endometrioma diameter impact serum anti-Müllerian hormone levels? A systematic review and meta-analysis.” Human reproduction open (2026). PMID: 42333302 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [447]
Bourdon M, Maignien C, Marcellin L et al.. “Distribution of endometriosis phenotypes according to patients' age in adult women with surgical evaluation.” Human reproduction (Oxford, England) (2024). PMID: 39186806 ↗
L4OTHERCited in: History and Evolution of Treatment, Special Populations - [448]
Tang X, Gu Z, Dai Y et al.. “Clinical features and long-term surgical outcomes of ureteral endometriosis with hydroureteronephrosis: a retrospective study.” BMC women's health (2026). PMID: 42426747 ↗
L2COHORTCited in: History and Evolution of Treatment - [449]
Lojanica MV, Ivanovic S, Milic N et al.. “Thoracic Endometriosis and Catamenial Pneumothorax: Imaging Pitfalls and an Integrated Diagnostic Approach.” Journal of clinical medicine (2026). PMID: 42355685 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [450]
Kahar KH, E-Anjum B, Nordin F et al.. “Building Disease Models for Endometriosis: iPSCs as Game-Changers.” International journal of molecular sciences (2026). PMID: 42353327 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [451]
. “ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.” Obstetrics and gynecology (2018). PMID: 29794680 ↗
L1GUIDELINECited in: Complications - [452]
. “Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.” Obstetrics and gynecology (2016). PMID: 27214185 ↗
L1GUIDELINECited in: Complications - [453]
. “ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.” Obstetrics and gynecology (2018). PMID: 29794673 ↗
L1GUIDELINECited in: Complications - [454]
Bougie O, McClintock C, Pudwell J et al.. “Long-term follow-up of endometriosis surgery in Ontario: a population-based cohort study.” American journal of obstetrics and gynecology (2021). PMID: 33894154 ↗
L3COHORTCited in: Complications - [455]
Luo S, Zhang C, Huang JP et al.. “Ultrasound-guided high-intensity focused ultrasound treatment for abdominal wall endometriosis: a retrospective study.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 28856852 ↗
L4COHORTCited in: Complications - [456]
Hilger WS, Magrina JF. “Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy.” Obstetrics and gynecology (2006). PMID: 17018497 ↗
L4CASE_REPORTCited in: Complications - [457]
Moawad NS, Santamaria Flores E, Le-Wendling L et al.. “Total Laparoscopic Hysterectomy Under Regional Anesthesia.” Obstetrics and gynecology (2018). PMID: 29742667 ↗
L4CASE_REPORTCited in: Complications - [458]
Haglund KE, Viswanathan AN. “Computed tomography-based radiation therapy of ovarian remnants for symptomatic persistent endometriosis.” Obstetrics and gynecology (2008). PMID: 18239029 ↗
L4CASE_REPORTCited in: Complications, Special Populations - [459]
Kill LM, Kapetanakis V, McCullough AE et al.. “Progression of pelvic implants to complex atypical endometrial hyperplasia after uterine morcellation.” Obstetrics and gynecology (2011). PMID: 21252784 ↗
L4CASE_REPORTCited in: Complications - [460]
Park BY, Yao R, Rossi J et al.. “Severe maternal morbidity associated with endometriosis: a population-based, retrospective cohort study.” Fertility and sterility (2023). PMID: 37030633 ↗
L3COHORTCited in: Complications - [461]
Zhang X, Chambers GM, Venetis C et al.. “Perinatal and infant outcomes after assisted reproductive technology treatment for endometriosis alone compared with other causes of infertility: a data linkage cohort study.” Fertility and sterility (2024). PMID: 39672363 ↗
L3COHORTCited in: Complications - [462]
Jacoby VL, Fujimoto VY, Giudice LC et al.. “Racial and ethnic disparities in benign gynecologic conditions and associated surgeries.” American journal of obstetrics and gynecology (2010). PMID: 20430357 ↗
L5REVIEW_NARRATIVECited in: Complications - [463]
Roman H, Bridoux V, Tuech JJ et al.. “Bowel dysfunction before and after surgery for endometriosis.” American journal of obstetrics and gynecology (2013). PMID: 23583209 ↗
L5OTHERCited in: Complications - [464]
Kondo W, Bourdel N, Tamburro S et al.. “Complications after surgery for deeply infiltrating pelvic endometriosis.” BJOG : an international journal of obstetrics and gynaecology (2010). PMID: 21083863 ↗
L4OTHERCited in: Complications - [465]
Aleksandrov A, Meshulam M, Smith AV et al.. “Fluorescence-guided management of deep endometriosis.” Fertility and sterility (2020). PMID: 32907747 ↗
L4CASE_REPORTCited in: Complications - [466]
Neblett MF, Youssef Y, Khan Z. “A step-by-step approach to a frozen pelvis.” Fertility and sterility (2022). PMID: 36456208 ↗
L4CASE_REPORTCited in: Complications - [467]
Aas-Eng MK, Lieng M, Dauser B et al.. “Transvaginal sonography determines accurately extent of infiltration of rectosigmoid deep endometriosis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 34182605 ↗
L2OTHERCited in: Complications - [468]
Aas-Eng MK, Dauser B, Lieng M et al.. “Transvaginal sonography accurately measures lesion-to-anal-verge distance in women with deep endometriosis of the rectosigmoid.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2020). PMID: 32068921 ↗
L2OTHERCited in: Complications - [469]
Jacobson TZ, Duffy JM, Barlow D et al.. “Laparoscopic surgery for subfertility associated with endometriosis.” The Cochrane database of systematic reviews (2010). PMID: 20091519 ↗
L1SR_OBSCited in: Complications - [470]
Ahmad G, Mackie FL, Iles DA et al.. “Fluid and pharmacological agents for adhesion prevention after gynaecological surgery.” The Cochrane database of systematic reviews (2014). PMID: 25005450 ↗
L1SR_OBSCited in: Complications - [471]
Vigano P, Corti L, Berlanda N. “Beyond infertility: obstetrical and postpartum complications associated with endometriosis and adenomyosis.” Fertility and sterility (2015). PMID: 26348274 ↗
L5REVIEW_NARRATIVECited in: Complications - [472]
Vercellini P, Crosignani PG, Somigliana E et al.. “Medical treatment for rectovaginal endometriosis: what is the evidence?” Human reproduction (Oxford, England) (2009). PMID: 19574277 ↗
L5REVIEW_NARRATIVECited in: Complications - [473]
Hall MS, Talge NM, Upson K. “Urinary cadmium and endometriosis prevalence in a US nationally representative sample: results from NHANES 1999-2006.” Human reproduction (Oxford, England) (2023). PMID: 37487110 ↗
L4OTHERCited in: Complications - [474]
Benaglia L, Candotti G, Papaleo E et al.. “Pregnancy outcome in women with endometriosis achieving pregnancy with IVF.” Human reproduction (Oxford, England) (2016). PMID: 27664955 ↗
L3OTHERCited in: Complications - [475]
Farland LV, Stern JE, Liu CL et al.. “Polycystic ovary syndrome and risk of adverse pregnancy outcomes: a registry linkage study from Massachusetts.” Human reproduction (Oxford, England) (2022). PMID: 36149255 ↗
L3OTHERCited in: Complications - [476]
Lemardeley G, Porcu-Buisson G, Pirrello O et al.. “Contribution of medico-administrative databases to health vigilance: example of post-oocyte retrieval infections.” Human reproduction (Oxford, England) (2024). PMID: 37953342 ↗
L2REVIEW_NARRATIVECited in: Complications, Prevention, Screening & Surveillance - [477]
Ding D, Wang Y, Wang H et al.. “Laparoscopy-assisted versus open surgery for reconstruction of abdominal wall defects following endometriosis resection: a retrospective cohort study.” Hernia : the journal of hernias and abdominal wall surgery (2026). PMID: 41995792 ↗
L3COHORTCited in: Complications - [478]
Amin A, Baryshnikov I, Shafique MA et al.. “Thoracic Endometriosis Syndrome: A Systematic Review and Meta-Analysis of Surgical Outcomes Among 1,182 Patients Over 25 Years.” Journal of minimally invasive gynecology (2025). PMID: 41419079 ↗
L1SR_OBSCited in: Complications - [479]
Hicks C, Leonardi M, Chua XY et al.. “Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39431364 ↗
L2COHORTCited in: Prognosis & Natural History - [480]
Thiel P, Bougie O, Pudwell J et al.. “Risk of Self-Harm Among Individuals Diagnosed With Endometriosis.” Obstetrics and gynecology (2025). PMID: 40811815 ↗
L3OTHERCited in: Prognosis & Natural History - [481]
Bulun SE, Yildiz S, Adli M et al.. “Endometriosis and adenomyosis: shared pathophysiology.” Fertility and sterility (2023). PMID: 36925057 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [482]
Suárez-Carrasco I, De Pedro MÁ, Pulido M et al.. “Stem cell therapy-based approaches in experimental endometriosis: a systematic review.” Reproductive biology and endocrinology : RB&E (2026). PMID: 41998676 ↗
L5SR_OBSCited in: Prognosis & Natural History - [483]
Sun R, Xu H, Ma R et al.. “Clinical and endocrine effects of pharmacological therapy in endometriosis: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41993993 ↗
L1SR_OBSCited in: Prognosis & Natural History - [484]
DiVasta AD, Feldman HA, Sadler Gallagher J et al.. “Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.” Obstetrics and gynecology (2015). PMID: 26181088 ↗
L1RCTCited in: Special Populations - [485]
Gao X, Outley J, Botteman M et al.. “Economic burden of endometriosis.” Fertility and sterility (2006). PMID: 17056043 ↗
L2SR_OBSCited in: Special Populations - [486]
Mousa NA, Bedaiwy MA, Casper RF. “Aromatase inhibitors in the treatment of severe endometriosis.” Obstetrics and gynecology (2007). PMID: 17540816 ↗
L4CASE_REPORTCited in: Special Populations - [487]
Thornburgh S, Farland LV, Harris HR et al.. “Disordered eating behaviors during adolescence and risk of endometriosis: a prospective cohort study.” Fertility and sterility (2026). PMID: 41519253 ↗
L2COHORTCited in: Special Populations - [488]
Pokoradi AJ, Iversen L, Hannaford PC. “Factors associated with age of onset and type of menopause in a cohort of UK women.” American journal of obstetrics and gynecology (2011). PMID: 21514918 ↗
L2OTHERCited in: Special Populations - [489]
Wu B, Yang Z, Tobe RG et al.. “Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 28613432 ↗
L2OTHERCited in: Special Populations - [490]
Wright KN, Laufer MR. “Endometriomas in adolescents.” Fertility and sterility (2010). PMID: 20334862 ↗
L4CASE_REPORTCited in: Special Populations - [491]
Orlando MS, Carey-Love A, Attaran M et al.. “Surgical techniques for excision of juvenile cystic adenomyoma.” Fertility and sterility (2022). PMID: 35931491 ↗
L4CASE_REPORTCited in: Special Populations - [492]
Çuvadar A, Guksu Z, Ateş S. “The Effects of Emotional Freedom Technique on Pelvic Pain and Quality of Life in Women Diagnosed with Endometriosis: A Randomized Controlled Trial.” Journal of integrative and complementary medicine (2025). PMID: 41313614 ↗
L1RCTCited in: Special Populations - [493]
Selak V, Farquhar C, Prentice A et al.. “Danazol for pelvic pain associated with endometriosis.” The Cochrane database of systematic reviews (2007). PMID: 17943735 ↗
L1SR_OBSCited in: Special Populations - [494]
Vercellini P, Buggio L, Berlanda N et al.. “Estrogen-progestins and progestins for the management of endometriosis.” Fertility and sterility (2016). PMID: 27817837 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [495]
Gabriel I, Vitonis AF, Missmer SA et al.. “Association between endometriosis and lower urinary tract symptoms.” Fertility and sterility (2022). PMID: 35109981 ↗
L4OTHERCited in: Special Populations - [496]
Yalew M, Lumsden AL, Mulugeta A et al.. “Risk factors of ovarian cancer: a systematic review and meta-analysis of Mendelian randomiation studies.” Journal of public health (Oxford, England) (2026). PMID: 42127414 ↗
L2SR_OBSCited in: Special Populations - [497]
Lin N, Zeleznik OA, Vitonis AF et al.. “Plasma metabolites associated with endometriosis in adolescents and young adults.” Human reproduction (Oxford, England) (2025). PMID: 40107296 ↗
L3OTHERCited in: Special Populations - [498]
Sasamoto N, Ngo L, Vitonis AF et al.. “Circulating proteomic profiles associated with endometriosis in adolescents and young adults.” Human reproduction (Oxford, England) (2022). PMID: 35770801 ↗
L3OTHERCited in: Special Populations - [499]
Shih YH, Wang SJ, Fan CT et al.. “Long-term risk of psychiatric disorders in women with endometriosis: A retrospective cohort study.” Comprehensive psychiatry (2025). PMID: 41308609 ↗
L3COHORTCited in: Special Populations - [500]
Neblett MF, Smith CY, Ainsworth AJ et al.. “Musculoskeletal disorders following hysterectomy with ovarian conservation: a population-based cohort study.” Menopause (New York, N.Y.) (2026). PMID: 41288454 ↗
L3COHORTCited in: Special Populations - [501]
Jing J, Qiao Y, Suginami H et al.. “Two novel serum biomarkers for endometriosis screened by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and their change after laparoscopic removal of endometriosis.” Fertility and sterility (2008). PMID: 19022433 ↗
L3RCTCited in: Prevention, Screening & Surveillance - [502]
Chan A, Gilks B, Kwon J et al.. “New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening.” Obstetrics and gynecology (2012). PMID: 22996112 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [503]
Orlando MS, Cadish LA, Shepherd JP et al.. “Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis.” American journal of obstetrics and gynecology (2022). PMID: 35490792 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [504]
Fernandes LFC, Ebaid GX, Bassi MA. “Bilateral ureteral endometriosis-an indolent, aggressive, and dangerous condition.” Fertility and sterility (2020). PMID: 33272615 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance - [505]
Karanjgaokar VC, Murphy DJ, Samra JS et al.. “Malignant transformation of residual endometriosis after hysterectomy: a case series.” Fertility and sterility (2009). PMID: 19800063 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance - [506]
Tang H, Yang X, Li Z et al.. “Association between female infertility and stroke mortality: evidence from the PLCO cancer screening trial.” Frontiers in endocrinology (2024). PMID: 39381444 ↗
L2RCTCited in: Prevention, Screening & Surveillance - [507]
Guo SW. “Endometriosis and ovarian cancer: potential benefits and harms of screening and risk-reducing surgery.” Fertility and sterility (2015). PMID: 26335131 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [508]
Kawwass JF, Crawford S, Session DR et al.. “Endometriosis and assisted reproductive technology: United States trends and outcomes 2000-2011.” Fertility and sterility (2015). PMID: 25881877 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [509]
Spivack LE, Glantz JC, Lennon C et al.. “Specificity of the lactate dehydrogenase isoenzyme index as a preoperative screen for uterine sarcoma before myomectomy.” Fertility and sterility (2020). PMID: 33070962 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [510]
Reis JL, Rosa NN, Ângelo-Dias M et al.. “Natural Killer Cell Receptors and Endometriosis: A Systematic Review.” International journal of molecular sciences (2022). PMID: 36613776 ↗
L3SR_OBSCited in: Prevention, Screening & Surveillance - [511]
Curchoe CL, Tarafdar O, Aquilina MC et al.. “SART CORS IVF registry: looking to the past to shape future perspectives.” Journal of assisted reproduction and genetics (2022). PMID: 36269502 ↗
L5SR_OBSCited in: Prevention, Screening & Surveillance - [512]
Seracchioli R, Mabrouk M, Manuzzi L et al.. “Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis.” Human reproduction (Oxford, England) (2009). PMID: 19625310 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [513]
Omwandho CO, Konrad L, Halis G et al.. “Role of TGF-betas in normal human endometrium and endometriosis.” Human reproduction (Oxford, England) (2009). PMID: 19892717 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [514]
Kiser AC, Hemmert R, Myrer R et al.. “Validation of administrative health data for the identification of endometriosis diagnosis.” Human reproduction (Oxford, England) (2025). PMID: 39704741 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [515]
Netter A, d'Avout-Fourdinier P, Agostini A et al.. “Progression of deep infiltrating rectosigmoid endometriotic nodules.” Human reproduction (Oxford, England) (2019). PMID: 31687764 ↗
L3OTHERCited in: Prevention, Screening & Surveillance - [516]
Guo SW, Du Y, Liu X. “Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis.” Human reproduction (Oxford, England) (2016). PMID: 27130956 ↗
L3OTHERCited in: Prevention, Screening & Surveillance